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Preface
Whereas epidemiological studies have increased our understanding and
knowledge regarding the role of cigarette smoking in the etiology of lung
cancer development, less is known about whether discontinuation of
smoking habits after diagnosis affects the prognosis of lung cancer patients.
Many prognostic factors in lung cancer have been described such as
morphological, molecular, and biochemical markers, and play important
roles in determination of disease course and patients' survival. Advances in
staging and classification of tumours as well as identification of potential
prognostic factors will help us to make correct, scientifically based
treatment decisions favourable to patients. Frequent review of established
and assessment of new prognostic factors are therefore required for creating
best treatment strategies.
Augsburg - Germany,            November 2004                               S.  P.  Deke
Contents                                                                                     Page
1.      Introduction……………............................................................  1 - 3
2.      Carcinogens and oxidants in cigarette smoke............................  3 - 11
2.1    Carcinogens................................................................................  3 - 6
2.2    Oxidants, ROS formation, and free radicals
         in cigarette smoke…………………….....……….……............  6 - 11
2.2.1 Evidences for cigarette smoke-induced oxidative stress............  8 - 11
3.      Factors contributing to lung cancer development…….......…..  11 - 19
3.1    Polymorphisms of important proteins (enzymes)
         involved in metabolism of tobacco carcinogens.......................  12 - 14
3.2    Polymorphisms in DNA repair genes, and genetic
         changes in repair proteins…………………….........................  15 - 19
4.      Effects of smoking in lung cancer patients...............................  20 - 46
4.1    Field cancerization theory in the lung.......................................  20 - 22
4.2    Smoking and risk of development of second
         primary lung cancer..................................................................  22 - 24
4.3    Cigarette smoke-induced modulation of macromolecules
         and signalling pathways: its role in tumour progression
         - metastasis, invasion, recurrence and therapy resistance
         in lung cancer............................................................................  25 - 36
4.3.1 Metastasis, invasion and recurrence.........................................  25 - 31
4.3.2 Multidrug resistance (MDR)....................................................  31 - 36
4.4    Disorders in the surfactant system due to cigarette
         smoke exposure........................................................................  38 - 39
4.5    Cigarette smoke-induced inflammatory processes
         in the lung.................................................................................  39 - 41
4.6    Cigarette smoking: important factor in the development
         of chronic obstructive pulmonary disease (COPD)..................  42 - 46
5.      Cigarette smoking, nicotine abuse and addiction……….........  46 - 48
6.      Effects of smoking cessation……………………...................  49 - 51
7.      Summary of the theoretical background.................................  52 - 56
8.      Patients and methods………………………...........................  56 - 69
8.1    Data acquisition and study population…….….…...................  56 - 68
8.2    Statistical data analysis............................................................  69
9.      Results….……….…………………………...........................  69 - 79
9.1    Overall survival time...............................................................  69 - 79
9.2    Outcome of therapy regime 1 (therapy results).......................  79
10.    Discussion……………………………….…………...………. 80 - 83
11.    Conclusion (with translation in German Language as
         "Zusammenfassung")...............................................................  83 - 90
12.    References................................................................................  90 - 96
13.    Acknowledgments (written in German Language as
         "Danksagung").........................................................................  97
14.    Curriculum vitae (written in German Language as
  "Lebenslauf")...........................................................................  98 - 99
- 1 -
1. Introduction
Cigarette smoking is the most important etiological factor in the causes of
development of lung cancer. In the early 50s scientists published articles
correlating tobacco smoking and carcinoma of the lung. Recent studies have
shown a strong coherence between the rising prevalence of lung cancer and
increasing cigarettes consumption. Tobacco use is estimated to be
responsible for almost 90% of all cases of primary pulmonary malignancies.
Cigarette smoking is also strongly associated with development of other
cancer types such as oral, laryngeal, bladder cancer as well as carcinoma of
the oesophagus. Smoking increases significantly the risks of development of
coronary artery disease, chronic obstructive pulmonary disease (COPD), and
other respiratory and vascular diseases. Smoking leads therefore to
increased morbidity and mortality due to cardiovascular, neoplastic, and
other related diseases [119].
Lung cancer remains the most frequently diagnosed malignant neoplasm
with enormous public health implications as it is one of the leading causes
of cancer mortality throughout the world. The cure rate of lung cancer using
the major currently existing treatment modalities (surgery, chemotherapy
and radiotherapy) is still very low and has not essentially improved for the
past 20 years. While localized and early stage disease can be cured by
surgery, the management of local advanced and metastasized pulmonary
malignancies frequently requires multimodal therapeutic approaches under
palliative aspect. In large measure, lung cancer patients are treated
palliative, either primarily or secondarily.  Although the implementation of
new treatment regimes using surgery, chemotherapy and/or radiotherapy has
improved the ability to prolong survival, the prognosis for the majority of
lung cancer patients remains still poor. The palliative treatment using the
present systemic or local anticancer therapies gives only moderate survival
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chance to inoperable patients or those who suffer from advanced disease.
The improvement of prognosis and quality of life (QOL), especially in
patients with advanced lung cancer, is therefore an important clinical issue.
Cigarette smoking affects physiological processes in various ways in the
body. Cigarette smoke (CS) is a complex mixture containing thousands of
chemical substances, some of which are toxic or carcinogenic. Moreover,
cigarette smoke contains and generates reactive oxygen species (ROS)
which can lead to oxidative stress in the lung and other organs. The
carcinogens, oxidants, and a number of toxic substances have direct or
indirect, modulatory or damaging effects on DNA, membrane lipids, cell
signalling proteins, and various macromolecules. These effects are
considered as the major paradigms by which many diseases such as lung
cancer and COPD develop [55,107].
Smoking cessation results have been poor among many lung cancer patients
as nicotine in cigarette smoke is a strong addictive substance. Despite the
fact that the survival expectancy of majority of lung cancer patients is very
limited, there are different opinions as to whether smoking cessation can
improve the overall survival and quality of life. At the same time, the abrupt
stop of tobacco consumption in nicotine-addicted patients may result in
withdrawal symptoms, leading to physical and psychovegetative reactions.
This may bring about negative effects on the expected quality of life
(quantity vs. quality of life). Although the benefits of quitting from smoking
have often been explained such as moderate improvement in lung function,
decrease in incidences of pulmonary symptoms and infections, as well as
better socio-environmental integration, the question of prognosis and quality
of life after smoking cessation among this patients' group is still open. The
following work will therefore review carcinogens and oxidants in CS, as
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well as discuss about important mechanisms and factors linking cigarette
smoking, lung cancer development and tumour progression (metastasis,
invasion, recurrence and therapy resistance). It will also focus on various
effects of tobacco smoke, including involvement of smoking in COPD
development, as well as possible withdrawal problems in nicotine-addicted
patients. It is thereby the major aim of this study to find out how the
prognosis of patients with advanced lung cancer can be influenced, if these
patients stop their smoking habits prior to beginning of palliative anticancer
therapy.  The major groups of this study include patients who stopped, and
those who continued smoking after histologically confirmed diagnosis of
small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
2. Carcinogens and oxidants in cigarette smoke
2.1 Carcinogens
Carcinogens are physical, biological, or chemical factors which can cause
development of malignant tumours. Tobacco smoke, which exists in two
major phases, namely the gas phase and particulate (tar) phase, has a large
number of chemical carcinogens. About 95% of CS is made up of gases,
mainly nitrogen, oxygen, and carbon dioxide. Using a glass-fiber filter, the
gas phase can be separated from the particulate phase, which contains about
3500 chemical compounds and the most of the carcinogens found in CS.
Both the mainstream cigarette smoke (MSCS) emerging from the
mouthpiece and the sidestream cigarette smoke (SSCS), which comes out
from the burning cigarette tip, contain carcinogens. So far, over 50 different
chemical carcinogens have been identified in CS. Some of the carcinogens
found in tobacco smoke are listed in the table below.
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Table 1: Some selected examples of carcinogens identified in cigarette
               smoke
Polycyclic aromatic hydrocarbons (PAHs)
Anthanthrene                                    Benzo(k)fluoranthane+
Benz(a)anthracene                            Cyclopenta(cd)pyrene
Benzo(a)pyrene+                              Dibenz(a,h)anthracene+
Benzo(b)fluoranthene+                     Dibenzo(a,i)pyrene+
Benzo(c)phenanthrene                     5-Methylchrysene+
Benzo(ghi)fluoranthene                    Indeno(1,2,3-cd)pyrene+
Benzo(ghi)perylene                          2,1-BNT
Benzo(j)fluoranthene+
Tobacco-specific N-nitrosamines (TSNAs)
NNK+                                             N-nitrosoanatabine
N-nitrosodiethylamine+                  N-nitrosoanabasine
N-nitrosodimethylamine                 N-nitrosopyrrolidine
N-nitrosonornicotine
Aromatic amines        Aza-arenes                              Inorganic substances
4-Aminobiphenyl       Benz(a)acridine                        Arsenic*
2-Aminophthaline      Benz(c)acridine                       Cadmium+
o-Toluidine                Dibenz(a,h)acridine+               Chromium+
                                  7H-Dibenzo(c,g)carbazole+     Hydrazine+
                                                                                    Nickel+
                                                                                    Polonium-210+
2,1-BNT  =  Benzo(b)naphtho(2,1-d)thiophene
NNK        =  4-(Methylnitrosoamino)-1-(3-pyridyl)-1-butanone
+              =  compounds which have convincingly shown pulmonary carcinogenecity in at least
                    one of the following laboratory animals (mouse, rat, hamster)
*               = lung or skin carcinogen as indicated by some epidemiological studies
[References: 35, 37, 52 - 56]
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However, only some of the above mentioned carcinogens will convincingly
induce lung tumours in laboratory animals or humans. Benzo[a]pyrene
(BaP), the most extensively studied carcinogen among the PAHs, can induce
lung tumours when administered local, systemic or via inhalation. In
laboratory studies, BaP induces lung tumours in rats and mice.
Dibenz[a,h]anthracene, dibenzo[a,i]pyrene, and 5-methylchrysene are
stronger pulmonary carcinogens than BaP, but are found in lower
concentrations in CS than BaP. The tobacco-specific N-nitrosamine NNK,
which is also a potent pulmonary carcinogen, possesses the ability to induce
lung tumours in all three commonly used rodent modals (rats, mice and
hamsters). This compound shows a remarkable organospecificity for the
lung and induces mainly adenoma and adenocarcinoma of the lung; an effect
that does not depend on the route by which it is administered. CS contains
substantially high amounts of NKK (80-770ng/cigarette), so that the total
dose experienced by a smoker in a lifetime of smoking is close to the lowest
total dose shown to induce lung tumours in laboratory animals. NNK
induces pulmonary malignant tumours via formation of alkylated
promutagenic DNA adducts such as O6-methylguanine (O6MG). N-
nitrosodiethylamine, which also belongs to the N-nitrosamines, has shown
pulmonary tumourigenic effect in hamsters. Its concentrations in CS are
lower than those of other carcinogens. Among the aza-arenes,
dibenz[a,h]acridine and 7H-dibenzo[c,g]carbazole have shown pulmonary
carcinogenic activity when tested in rats and hamsters [55].
Some miscellaneous organic compounds found in CS are also pulmonary
carcinogens. 1,3-butadiene and ethyl carbamate have shown tumourigenic
potential in mice. Inorganic substances such as nickel, chromium, cadmium,
arsenic, hydrazine, and polonium-210 are all present in CS in different
concentrations which show carcinogenic activity in different animal species,
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including rats, mice, and hamsters. Many substances in CS may also act as
co-carcinogens (promoters), among them catechols, methylcatechols,
VHPLTXLQRQHV S\URJDOORO GHFDQH DQG XQGHFDQH 0RUHRYHU WKH .
unsaturated aldehydes (acrolein and crotonaldehyde) abundantly present in
CS are strongly toxic to cells and cilia of the bronchial system. Other
compounds in CS such as formaldehyde and acetaldehyde may also have
carcinogenic effect on the lung [54].
2.2 Oxidants, ROS formation, and free radicals in cigarette smoke
As a result of metabolic and biochemical processes as well as external
factors ROS are continuously formed in the lung and other organs of the
body. For instance, mitochondria produce a substantial amount of ROS (e.g.
ÂO2– and H2O2), which are normally broken down by GSH-dependent
peroxidase-catalysed reactions. ROS production is also used by reactive
phagocytic cells to destroy microorganisms. Being atoms or molecules, ROS
can possess unpaired or paired electrons and are characterised by a
particularly high affinity to undergo redox reactions with a number of
macromolecules in the body including membrane lipids, cell-signalling
proteins, regulatory enzymes, and DNA. Redox modifications of these
macromolecules may imply an important functional or structural change to
organs. In physiological conditions cells are able to retain redox equilibrium
by means of different antioxidant defence systems. Shift of this equilibrium
in favour of oxidants leads to inefficient cell protection against noxious
effects of ROS and may result in oxidative organ damage [88].
Tobacco smoke is one of the important sources of ROS and plays a
significant role in increased oxidative DNA damage and modulation of
different biochemical pathways in normal and neoplastic lung cells.
Nicotine abuse leads therefore to excessive oxidative burden to lung cancer
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patients. Cigarette smoke is a complex mixture of more than 4,700 chemical
compounds, including high concentrations of free radicals and other
oxidants. Free radicals in CS are derived from both the gas and the
particulate phase. Pryor and Stone [108] have reported that the gas-phase CS
contains approximately 1015 radicals per puff, primarily of the alkyl and
peroxyl types. In addition, nitric oxide (NO) is present in high
concentrations in CS (500 - 1000 ppm). Nitric oxide reacts quickly with
superoxide anion (ÂO2–) to form peroxynitrite (ONOO–), and with peroxyl
radicals to give alkyl peroxynitrites (ROONO). Cigarette smoke tar contains
more than 1018 free radicals per gram. The radicals in the particulate phase
of CS are more stable and predominantly organic. The quinone-
hydroquinone complex forms the major free radical species in this CS
phase. It is hypothesized that the tar radical system exists in an equilibrium
mixture composed of quinones, semiquinones and hydroquinones. It is
suggested that the quinone-hydroquinone complex forms a redox cycling
system that can generate ÂO2– from molecular oxygen and leads ultimately
to formation of hydrogen peroxide (H2O2) and hydroxyl radical (ÂOH).
Whereas short-lived radicals in the gas phase of CS may be quenched
immediately in the ELF redox reactions in cigarette smoke condensate
(CSC), which forms in the epithelial lining fluid, may produce ROS for a
considerable time. Moreover, CSC can react with or complex some metal
cations (e.g. Fe3+, Cu2+), followed by their release or deposition in the lung.
Cigarette tar semiquinone is an effective metal chelator and can bind iron to
produce the tar-semiquinone + Fe¦+, which generates H2O2. Cigarette
smoking results also in iron being released from ferritin. Since iron is
strongly catalytic in many redox reactions, it can participate in generation of
ROS and free radicals. In presence of free iron or copper ions, the strongly
reactive ÂOH is formed from the less reactive H2O2. Following CS exposure,
additional oxidants, free radicals and ROS, are generated by inflammatory
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cells in the lung. Whereas a nitric oxide synthetase (NO-synthetase) is
responsible for the NO synthesis in macrophages, neutrophils do possess
myeloperoxidase (MPO), an enzyme that produces HOCl, an oxidation
product of chloride ions (Cl–). In response to CS, reactive phagocytes,
including monocytes, neutrophils, and alveolar macrophages (AM), do
produce and release ÂO2– and NO,  which can react together to produce a
highly reactive ONOO– [10,36].
2.2.1 Evidences for cigarette smoke-induced oxidative stress
There are different ways by which oxidative stress in the body can be
detected following exposure to CS. These include analysis of various
antioxidant defence mechanisms, analysis of molecular and biochemical
products of oxidative stress, and pulmonary inflammatory and immune
responses. Detection of oxidative stress following cigarette smoking can be
done in lung tissues, respiratory epithelial lining fluid (RELF), breath,
blood, and excretory body fluids such as urine. Different antioxidant
defence mechanisms may involve antioxidant enzymes, metal-binding
molecules, and some micronutrients such as vitamins. Important enzymes
involved in the antioxidant defences are the glutathione system (GSH-
GSSG),  superoxide dismutase (SOD), and catalase. Substances such as
ascorbic acid (vitamin C), α-tocopherol (vitamin E), β-carotene, albumin-
SH, uric acid, bilirubin, and iron or copper binding proteins like transferrin,
ferritin and coeruloplasmin, are also essential in conferring protection
against oxidative stress [34].
In a study conducted by Abou-Seif [1], smoking was associated with a
decrease in plasma concentrations of vitamin E and C, uric acid, and
ceruloplasmin. Moreover, while the blood glutathione peroxidase (GPx)
activities were decreased, the activities of catalase, erythrocyte and plasma
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SOD were elevated in smokers compared to the corresponding levels of the
control individuals, showing that tobacco use is associated with oxidative
stress which leads to depletion of some antioxidant systems as well as
activation of antioxidant enzymes SOD and catalase which act against
oxidative stress. Similar results were obtained in the study of Lykkesfeldt et
al. [82].  Using an enzyme-linked assay  for ascorbic acid (reduced form)
and its oxidised form, dehydroascorbic acid, it could be observed that
smoking was associated with depletion of the ascorbic acid pool and
reduced capacity to maintain ascorbic acid in its reduced form in the plasma,
suggesting that smoking leads to oxidative stress.
Despite continuous extensive repair, oxidatively modified DNA is abundant
in normal and neoplastic tissues. The accumulation of damaged nucleosides
takes place in both nuclear and mitochondrial DNA. The molecular
biomarkers of oxidative DNA damage include modifications in DNA
isolated from target tissues or cells, and urinary excretion of oxidised
nucleosides and bases as repair products. In a molecular biology laboratory
study conducted by Howald et al. [63], mice were subjected to CS. After
30min. single and triple CS exposure, a DNA analysis of tissues from lung,
heart, and liver revealed a significant increase of the presence of the
oxidative product 8-hydroxy-2'-deoxyguanosin (8-OHdG) above the control
levels. While the tissues of group 1 animals were analysed immediately
following the CS exposure, group 2 animals were allowed to rest for 90min.
prior to excision and analysis of the tissues. For the single exposure 8-
OHdG lung values, group 1 showed an increase of 40% over the control.
Group 2 was greater than control by 99%. This suggests that the mouse lung
continues to produce 8-OHdG during the rest non-exposure period. For the
triple exposure, the 8-OHdG levels in the lung of group 1 mice increased
over control by 63%, and group 2 increased by 54%. The decrease in group
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2 levels of 8-OHdG is probably due to repair of some of the DNA damage
during the rest period.
To evaluate the effect of cigarette smoking on oxidative stress in the human
lung, Asami et al. [6] compared levels of the oxidative DNA adduct 8-
OHdG in lung tissues from 14 smokers, 7 ex-smokers and 9 non-smokers.
The mean level of 8-OHdG in the lung tissues from smokers was 1.43-fold
higher than that of non-smokers with a statistically significant difference of
p = 0.0262. There was also a positive correlation for the levels of this
oxidative DNA damage product in normal lung tissues and the number of
cigarettes smoked per day (p = 0.0132). Similar results were also
demonstrated by Prieme et al. [106], who had carried out a study to
investigate the effect of smoking on oxidative DNA modification. The
analysis for the content of oxidised nucleoside 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxodG) in 24-h urine samples collected from all test
persons demonstrated that smoking was associated with increased urinary
excretion rate of 8-oxodG. Upon smoking cessation, the oxidative DNA
damage was significantly reduced. As with other oxidative DNA lesions,
tobacco smoking has consistently been shown to increase the urinary
excretion rate of 8-oxodG by 30 – 50%.
Evidence of increased oxidative stress following CS exposure can also be
analysed in the blood by measuring the Trolox equivalent anti-oxidant
capacity (TEAC) of plasma and the levels of products of lipid peroxidation
as indices of overall oxidative stress. In a study, chronic smoking was
associated with reduced plasma TEAC and increased levels of lipid
peroxidation products, suggesting that smoking leads to an
oxidant/antioxidant imbalance due to oxidative stress [109]. One of the
important oxidant-induced products of lipid peroxidation is 8-isoprostane, a
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prostaglandin-F2 isomer that is formed in vivo by free radical-catalyzed
peroxidation of arachidonic acid. This product can be detected in plasma,
breath, or urine of individuals subjected to oxidative stress. Montuschi et al.
[97] quantified oxidative stress in lungs in patients with COPD and in
healthy smokers, as reflected by 8-isoprostane concentrations in breath
condensate. This is a non-invasive method to collect airway secretions. The
acute effect of smoking on exhaled 8-isoprostane in healthy smokers was
assessed. Exhaled 8-isoprostane was measured by a specific enzyme
immunoassay in 10 healthy non-smokers and 12 smokers, 25 COPD ex-
smokers, and 15 COPD current smokers. 8-Isoprostane concentrations were
similar in COPD ex-smokers (40 + 3.1 pg/ml) and current smokers (45 + 3.6
pg/ml) and were increased about 1.8-fold compared with healthy smokers
(24 + 2.6 pg/ml, p < 0.001), who had 2.2-fold higher 8-isoprostane than
healthy non-smokers (10.8 + 0.8 pg/ml, p < 0.05). Smoking caused an acute
increase in exhaled 8-isoprostane by about 50%. The study showed that free
radical production is increased in patients with COPD and that smoking
causes an acute increase in oxidative stress. Other biomarkers for estimation
of the extent of CS-induced oxidative stress are the level of oxidised
methionine in exfoliated bronchial epithelial lining cells, exhalation of
hydrogen peroxide and carbon monoxide, xanthine/xanthine oxidase activity
in broncho-alveolar lavage fluid (BALF), as well as plasma protein
carbonyls and plasma protein sulfhydryl oxidation.
3. Factors contributing to lung cancer development
Lung cancer is largely due to "chronic" exposure of respiratory epithelial
cells to carcinogens such as those in CS. As mentioned earlier, tobacco use
contributes the greatest part of cases of pulmonary malignancies. The risk of
developing lung cancer is directly related to the extent of cigarettes
consumption, given in number of pack-years, and defined as the product of
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the average number of packs of cigarettes (20 cigarettes/pack) smoked per
day multiplied by the number of years smoked. However, the influence of
malignancy seems to include a combination of carcinogen exposure, genetic
predisposition, immunological factors, viral infections, dietary factors, and
exposure to alcohol. Genetic factors determining individual susceptibility to
lung cancer development may include differences in expression of important
proteins (enzymes) involved in metabolic pathways of tobacco carcinogens,
as well as polymorphisms in genes responsible for repair of damaged or
adducted DNA.
3.1 Polymorphisms of important proteins (enzymes) involved in
      metabolism of tobacco carcinogens
(a) Cytochrome P450 gene products
Several studies have investigated the correlation between genetic
polymorphisms and susceptibility to malignancy. These studies regarding
cytochrome P450 polymorphisms in cancer have provided mechanistic
insights into cancer susceptibility with the goal of identifying individuals at
a high risk. Hepatic and extrahepatic polymorphic cytochromes P450
(CYP450) are involved in metabolism of tobacco carcinogens. A number of
substances contained in CS can act as inducers, substrates or inhibitors of
CYP450. Important CYP450 isoenzymes involved in the lung
carcinogenesis by converting some procarcinogens into potent carcinogenic
metabolites in tobacco smoke are CYP1A1, 1A2, 2A6, 3A4, 2Cs (e.g. 9, 17,
and 19), 2D6, and 2E1,. In particular, lung cancer has been extensively
studied with respect to interactions between CS carcinogens and their
metabolizing enzymes [9,137].
The CYP2E1 gene product, which is expressed in human lung, liver, kidney
and brain, is involved in metabolism of low-molecular-weight compounds,
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including ethanol, 1,3-butadiene, and tobacco smoke N-nitrosamines (N-
nitrosodimethylamine, N-nitrosodiethylamine, and NNK). The possible
association of CYP2E1 polymorphisms with lung cancer has been discussed
elsewhere [123]. Consistent with the role for N-nitrosamines in lung cancer
development, the polymorphic CYP2E1c1/c1 genotype has shown a 15-fold
increase in lung cancer risk in an epidemiological study involved test
individuals from different ethnic groups in the USA [147]. In this study,
individuals with the susceptible CYP2E1c1/c1 genotype appeared to have
developed cancer at an earlier age and with lower cigarette pack-year of
exposure than did patients with the c1/c2 or c2/c2 genotypes. Therefore, the
data suggest that individuals who lack a c2 allele might be at higher risk for
developing lung cancer.
In another similar study, Yamaziki et al. [151] examined the roles of
cytochrome P450 enzymes in the activation of the tobacco-smoke related
nitrosamines N-nitrosodiethylamine, N-nitrosodimethylamine, N-
nitrosonornicotine, NNK and its metabolic alcohol product 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human liver microsomes.
They demonstrated that CYP3A4, CYP2D6 and CYP2Cs (9, 17 e.t.c) are
not extensively involved in the activation of these nitrosamines, but that
CYP2E1 and CYP2A6 were the most important enzymes in catalysing the
metabolic activation of nitrosamines. The function and structure of CYP2E1
are highly conserved across species. CYP2E1 is slightly induced in the liver
by CS, but its pulmonary expression is substantially more inducible (6.8-
fold) than that of CYP1A1 (2-fold), All these studies suggest therefore that
CYP2E1 may actively participate in pulmonary carcinogenesis induced by
CS.
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(b) Glutathione S-transferase gene products
Glutathione S-transferases (GSTs) are important enzymes in detoxification
processes in rodents. GSTM1 gene codes for M or mu class glutathione
transferases that are involved in detoxification of various pulmonary
carcinogens including metabolic activation products of PAHs (e.g. PAH diol
epoxides) and CS oxidants. Other human glutathione S-transferases include
GSTA, GSTP, and GSTT (alpha, pi, and theta classes). Almost 40%-50% of
the human population possess the GSTM1 null genotype [123]. An
increasing evidence from various studies show that there is a relationship
between GSTM1 null and lung cancer risk. It is hypothesized that the lung
cancer risk is elevated in individuals possessing GSTM1 null genotype. The
collective data of these studies suggest that there may be a close link of
GSTM1 null with lung cancer. A recent study could show a higher lung
cancer risk in females than males with GSTM1 null [130]. GSTP1-1 and
GSTA1-1 also are important enzymes involved in catalysis of glutathione
conjugation of CS carcinogens such as the bioactivated form of BaP,
benzo(a)pyrene diol epoxide (BPDE), and other PAH diol epoxides [129].
However, the detoxification of PAH metabolites is a complex process which
may need the presence of two or more gene products. The content of GSTP1
in the human lung exceeds that of GSTM1. Other enzymes such as uridine-
5'-diphosphate-glucuronosyl transferase (UGT) and dihydrodiol
dehydrogenase (DHD) are also involved in metabolic pathways of tobacco
smoke carcinogens and may play an important role in determination of
individual lung cancer risk.
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3.2 Polymorphisms in DNA repair genes, and genetic changes in
      repair proteins
Although lung cancer is the paradigm of tobacco-induced malignancies,
host-specific factors seem to modulate individual susceptibility to CS-
induced carcinogenesis. Variations in DNA repair capacity (DRC) may
influence the rate of removal of DNA damage and fixation of mutations. As
a proxy for DRC, mRNA levels of different DNA repair genes can be used.
These mRNA expression levels can be obtained by means of different
assays (e.g. multiplex reverse transcriptase-PCR assay) in mitogen-
stimulated or unstimulated human peripheral blood lymphocytes, or in other
rapid proliferating tissues such as skin, ovary, testis, prostate, liver and
intestine [32].
There are three mechanisms of DNA repair: direct repair (DR), base
excision repair (BER) and nucleotide excision repair (NER). These topics
have been reviewed elsewhere [114,121]. As indicated by some studies,
individuals with reduced DRC are at higher risk of developing lung cancer.
It is also reported that lung cancer patients have often been observed to have
suboptimal cellular DRC and therefore more promutagenic DNA alterations
than healthy individuals [117,143]. Several genes and repair proteins
(enzymes) are involved in the DRC, some of which are the xeroderma
pigmentosum complementary groups (e.g. XPA, B, D, F and G), x-ray
repair cross-complementing groups (e.g. XRCC1 and 3), excision repair
cross-complementing groups (e.g. ERCC1, 2, 3, 5, and 6 ), Cockayne's
syndrome complementary group B (CSB) and apurinic/apyrimidinic
endonuclease/redox factor-1 (APE/ref-1). The DNA repair protein O6-
alkylguanine-DNA alkyltransferase (AGT), that encodes the human O6-
methylguanine-DNA methyltransferase (MGMT), and the human cytosine-
DNA methyltransferase-3B (DNMT-3B) are also important in cellular
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defence against promutagenic effects of carcinogens. Furthermore, the
enzyme 8-oxoguanine-DNA N-glycosidase (8-OGG) is also involved in
repair of oxidative DNA damage [12, 95]. However, only some of the above
mentioned DNA repair genes have extensively been studied and
convincingly shown to play an important role in the DRC in the lung.
(a) Xeroderma pigmentosum complementary groups
The xeroderma pigmentosum complementary group A (XPA), a DNA
binding protein in the NER pathways, modulates damage recognition of
DNA. It is well known that NER deficiency is associated with a decreased
DRC and hence an increased risk of lung cancer. Recently, a common
single-nucleotide polymorphism (A-->G) was identified in the 5' non-coding
region of the XPA gene. The two common polymorphisms of the XPA gene
are A23G and G709A, with possible AA, AG and GG genotypes. On testing
individuals from different ethnic groups for DRC and hence lung cancer
risk, Park et al. [102] observed that male subjects with two G alleles (GG
genotypes) demonstrated more efficient DRC than did those with
homologous A alleles (AA genotypes). However, Wu et al. [148] found out
that at least one G allele (e.g. AG, GG phenotypes) is enough to reduce CS-
induced lung cancer risk to a significant level.
The DNA repair protein xeroderma pigmentosum complementary group D
(XPD) is involved in both, NER and BER of DNA lesions induced by
tobacco and environmental carcinogens. Polymorphisms in the DNA repair
gene XPD have been associated with risk of developing different cancer
types such as bladder, oesophagus and lung cancer [126,150]. Many studies
have focused on the functional impact of the commonly known
polymorphisms in XPD exon 10 (G-->A, Asp312Asn) and exon 23 (A-->C,
Lys751Gln). On assessing XPD polymorphisms at codon 312, smoking, and
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lung cancer risk, one study [149] found an increased risk of squamous-cell
carcinoma (SCC) in individuals who carried at least one 312Asn variant
allele compared with those who had the 312Asp/Asp genotype. At codon
751, subjects with at least one variant 751Gln allele were at a borderline
increased risk of SCC of the lung compared with those having 751Lys/Lys
genotype. A multiplicative interaction between cigarette smoking and the
Asp312Asn polymorphism on risk of SCC was also observed. Other studies
could also come out with similar results [62, 80]. Therefore, XPD codon 751
polymorphism (Lys-to-Gln amino acid change) and XPD codon 312 (Asp-
to-Asn amino acid change) may affect the repair of smoking-induced DNA
damage and be associated with increased lung cancer risk.
Jeon et al [68] investigated the relationship between the polymorphism in
the xeroderma pigmentosum complementary group G (XPG) gene at codon
1104 and the risk of lung cancer in a study population consisted of almost
equal number of lung cancer patients and healthy controls. In this age and
sex matched study, the Asp/Asp genotype was more frequent in the controls
than in the cases, and associated with a significantly decreased lung cancer
risk. Older subjects, males, and lighter smokers were significantly more
protected by Asp/Asp genotype than others against lung cancer
development. Histologically, the Asp/Asp genotype showed a significant
decrease in risk of squamous-cell carcinoma. These results were obtained
when combined His/His and His/Asp genotype was used as the reference
and suggest that the XPG codon 1104 (His1104Asp) polymorphism
contributes to genetic susceptibility to lung cancer development.
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(b) X-ray repair cross-complementing groups
The x-ray repair cross-complementing group 1 (XRCC1) is mainly involved
in BER of DNA repair pathways. Polymorphisms of DNA repair gene
XRCC1 have recently been identified; and growing evidence shows that
these polymorphisms may have some phenotypic significance regarding
smoking-related cancer risk. With regard to the XRCC1 gene and the cancer
risk in different malignant tumours (breast, gastric, and lung cancer),
polymorphisms at codons 194 (Arg-->Trip) and 399 (Arg-->Gln) have been
extensively studied. At codon 399 (Arg/Gln), a nucleotide substitution of
guanine to adenine leading to non-conservative amino acid change has been
identified. This amino acid change is believed to be associated with
increased levels of aflatoxin B1-adducts and glycophorin A somatic
mutations. In a molecular biology study, XRCC1 genotypes were assessed
at codon 399 in patients with adenocarcinoma of the lung and cancer-free
controls in two ethnic populations. The distribution of XRCC1 genotypes in
the study population differed between cases and controls; and all three
possible genotypes (Arg/Arg, Arg/Gln, Gln/Gln) could be found between
the subjects. The study showed an increased lung cancer risk in subjects
with Gln/Gln genotype. The elevated cancer risk related to ethnicity, age
and smoking [40].
(c) DNA repair protein O6-methylguanine-DNA methyltransferase
      and related proteins
The DNA repair protein O6-methylguanine-DNA methyltransferase
(MGMT), codes for the human protein O6-alkylguanine-DNA
alkyltransferase (AGT), and is responsible for the repair of O6-
methylguanine-DNA (O6MG-DNA) adducts which are usually induced by
NNK in CS. Overexpression of MGMT has been associated with increased
repair capacity for O6MG-DNA adducts, decreased mutational activation of
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K-ras oncogene, and hence reduced lung tissue susceptibility to NNK-
induced tumourigenesis. Loss of expression of MGMT is rarely due to
deletion, mutation, or rearrangement of the MGMT gene, but promoter
hypermethylation (e.g. methylation at CpG sites) of MGMT has been
associated with inactivation of the gene and increased G to A mutations in
K-ras in colorectal cancer, and increased G to A transitions in the p53 gene
in NSCLC, particularly in adenocarcinomatous cell lines [43,145].
The expression of the human cytosine-DNA methyltransferase-3B (DNMT-
3B) is regulated by methylation of promoter region of the gene.
Polymorphisms in this NER gene are also believed to be associated with
increased lung cancer risk. A C to T transition at a novel promoter region of
the protein has recently been identified. This polymorphic transition
increases the promoter activity. In a study, promoter polymorphism of the
gene leading to CT heterozygotes was associated with over 2-fold risk
increase of lung cancer compared to CC homozygotes. With regard to
polymorphisms or low activity of 8-oxoguanine-DNA N-glycosidase (8-
OGG), the high risk of lung cancer development seems to have a cumulative
effect with smoking status. 8-OGG is expressed in the lung tissue, and
involved in the BER of 8-OHdG DNA adducts that are formed during CS-
induced oxidative stress [104,118]. In short, the individual overall
susceptibility to lung cancer development may depend on the balance
between carcinogen metabolic activation and detoxification, as well as the
rate at which CS carcinogen-induced DNA damage is repaired. This is an
area which needs further investigations.
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4. Effects of smoking in lung cancer patients
Tobacco consumption plays a remarkably significant role in genetic damage
and hence lung carcinogenesis. Continuation of cigarette smoking implies a
prolonged exposure of the bronchial system to carcinogens and oxidants.
This provides a possibility of induction of further molecular alterations to
normal, preneoplastic, and neoplastic lung cells. Early preneoplastic
morphological changes may bypass further steps and progress to invasion.
Progressive molecular changes in pre-existing tumours may give rise to
altered phenotypes or aggressive characters of the tumours, leading to
important therapeutic and prognostic consequences.
Apart from carcinogenic effect, smoking may lead to a number of
nonneoplastic lung disorders which can influence the disease course and
prognosis of lung cancer patients. Many diseases caused or facilitated by
smoking habits may play part in the multimorbidity and reduction of
survival expectancy of lung cancer patients. One of the most important
nonmalignant pulmonary diseases is COPD, which is mostly accompanied
with impaired lung function.
4.1 Field cancerization theory in the lung
Considering the lung of long-term smokers as an organ with a very high
exposure to carcinogens, the field cancerization theory can be applicable in
explanation of all possible genetic changes existing in different cells of the
bronchial epithelial lining and the underlying probability of development of
lung cancer. This theory is commonly applied to head and neck squamous-
cell carcinoma (HNSCC) and hypothesizes that the entire epithelial surface
of the upper aerodigestive tract has an increased risk for development of
(pre)malignant lesions due to multiple genetic abnormalities as the result of
exposure to various carcinogens. In the lung, this hypothesis is favoured by
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multiple molecular changes and high incidence of preneoplastic lesions
found in lung cancers. This suggests that inside the carcinogen-exposed field
there are multifocal clones with different phenotypes. The differences in
mutation spectra arising from differing selectivity of carcinogens may
provide important clues in the knowledge of the cause of lung cancer
(hotspots theory). The theory of multifocal lesions in the field cancerization
supports therefore the use of genetic markers in the differential diagnosis of
recurrence of first primary tumours or metastases from second primaries
after successful "radical" resections of tumours [59, 67, 89].
However, there are alternative theories regarding the occurrence of multiple
(pre)malignant lesions. These theories which have been proposed in the last
decade are based on the premise that cell transforming events are generally
rare and that the multiple lesions arise due to widespread migration of
transformed cells in the whole field of cancerization. In the concept of these
theories, intraluminal migration in the lung might involve movement of
neoplastic cells by bronchial mucus (micrometastases), or intraepithelial
migration of the progenitor cells of the initially transformed cells. In order to
get a consensus about these different theories, different ways of
investigation may be used, among them analysis of differences in genetic
alterations between histologically normal tumour-adjacent mucosal cells
(TAMC) from smokers and those from non-smokers. Migrating tumour cells
are likely to be found in TAMC from both smoking and non-smoking lung
cancer patients. Thus, TAMC from smoking and non-smoking lung cancer
patients with the same histology should exhibit the same molecular
alterations. These alterations should not be found in smoking or non-
smoking healthy individuals, as in those cases, there is no source for
migrating tumour cells. Moreover, any observed alterations in TAMC
should be identical with the alterations in the primary carcinoma, in case of
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migration of cells from the pre-existing tumour. In case of migration of
progenitor cells, at least some early tumourigenic alterations would be
identical between primary tumour and TAMC. In absence of migrating cells,
changes in TAMC of smoking patients should be absent in non-smoking
patients and regarded as smoking-induced independent events [48, 49,142].
The other way to investigate these different theories is to investigate the
clonal expansion of multiple (pre)malignant lesions by analysis of early
genetic alterations in the course of development of lung cancer. Separate
lesions would share common genetic alterations if they would have
developed from a single clone. Clonal relationship between different
multiple lesions points to migration of tumour or progenitor cells. If no
clonal relationship between different lesions can be observed, it is likely that
the lesions developed independently from each other [65].
4.2 Smoking and risk of development of second primary lung cancer
Many studies have been carried out to investigate the risk of developing
second primary lung cancers among patients with initial lung cancer. In
some of these studies, cigarette smoking has been condemned as one of the
important factors for increased risk of development of second lung cancers.
In addition, anticancer treatment modality has shown a certain correlation
with the risk. Tucker et al. [133] found significant increase (about 3.5-fold)
of second lung cancers among lung cancer patients compared to the general
population. Moreover, this study revealed a correlation between the risk,
treatment modality, and smoking habits. The second cancer risk seemed to
increase with chest irradiation (13-fold). A relative risk of 21-fold showed
an interaction between radiotherapy and cigarette smoking. While treatment
with various forms of polychemotherapy had comparable overall risk
increases of 9.4- to 13-fold, continuation of smoking habits had a 19-fold
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risk increase among subjects treated with alkylating agents. These results
did not differ from those of Johnson et al. [69] and Yoshida et al. [153], who
found out that an increased relative risk of second primary cancer in patients
treated for small-cell lung cancer was associated with smoking and family
history of cancer. Other studies which investigated the impact of smoking
cessation came out with results that showed significant decrease in risk of
developing second primary cancers after successful treatment of patients
with initial lung cancers [71,112].
The study of Kelley et al. [74] concerning genetic analysis on second
primary cancers in lung cancer patients is an important step which increases
our understanding regarding the validity of field cancerization theory in the
development of pulmonary malignancies. In patients surviving small-cell
lung cancer, cigarette smoking led to development of smoking-associated
tumours which had genetic and morphological features consistent with non-
small-cell carcinomas. These results could be supported by Godschalk et al.
[49] who analysed the effect of smoking and the presence of miscoding
multiple DNA adducts of oxidative stress O(4)-ethylthymidine (O(4)etT)
and of the CS carcinogens (PAHs) in tumour adjacent normal lung tissues of
smokers and non-smokers operated lung cancer patients. They concluded
that the O(4)etT and PAH-DNA adduct levels were higher in lung DNA of
smokers than non-smokers. These miscoding lesions contribute to increased
genomic instability and elevated lung cancer risk in smokers, and may
therefore lead to development of second tumours. All these studies have
therefore provided hints that smoking among lung cancer patients may lead
to development of further primary carcinomas. The only question to be
answered in all these study results is whether the second primary tumours
emerge as a result of pre-existing genetic alterations due to long-term
smoking history of the patients, or as a result of new genetic changes due to
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prolonged exposure to CS after diagnosis of the first tumours. It may be
possible that both factors are responsible for development of new primary
tumours.
Carcinogenesis is a process believed to take place over years or decades.
This may raise an argument that patients under palliative treatment of
advanced lung cancer would not succumb to new primary tumours if they
continue their smoking habits as they hardly have a year to survive. But on
the other hand, the time interval for development of lung cancer from
preneoplastic lesions is not the same for all patients with equal-term
smoking history and level. Moreover, not everybody who smokes develops
a carcinoma. It is believed that only 11% of tobacco smokers develop
manifest lung cancer [2], suggesting that many factors may determine
individual susceptibility to eruption of carcinomas among those who are
exposed to carcinogens. Synergistic effects of different factors, including
pre-existing individual genetic factors, molecular changes acquired by
smoking habits, as well as weaken or failure of immunological surveillance,
may have decisive role in determination of latent time between promotion
and progression. Weaken or failure of immunological surveillance may be
not only due to various diseases or other internal and external factors such as
CS [22,100], but also physiologically due to advanced age [7]. This might
explain the pattern of age distribution of lung cancer patients, since majority
of them age over 55 years. Therefore, people who have once developed lung
cancer may be predisposed to development of further primary carcinomas.
In this case, preneoplastic lesions may progress to malignancies after a short
latent time as response to prolonged exposure to carcinogens CS. In this
manner, continuation of smoking habits may accelerate lung cancer
progression.
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4.3 Cigarette smoke-induced modulation of macromolecules and
      signalling pathways: its role in tumour progression - metastasis,
      invasion, recurrence and therapy resistance in lung cancer
4.3.1 Metastasis, invasion and recurrence
(a) Protein kinases
There is an increasing evidence that protein kinase C (PKC), a family of
numerous closely related isoforms, has a deep implication in carcinogenesis
as well as in metastatic and invasive processes of different malignancies.
However, little is known on the specific role of each isoform of the enzyme
in these processes. PKC plays an important role in signal transduction
pathways. As a cell-signalling protein, PKC has both an N-terminal
regulatory and a C-terminal catalytic domain. The catalytic subunit is a
target for chemoprotective antioxidants which cause down-regulation of the
enzyme. On the contrary, oxidants predominantly react with the regulatory
subunit and activate PKC-mediated cellular signal transduction. Activation
or inhibition of PKC activity indicates to play a critical role in regulation of
some cellular events such as mitogenesis, cell adhesion, apoptosis,
angiogenesis, and metastasis. These are key events related to tumour
promotion and invasion. The PKC-mediated tumour promotion by oxidants
appears due to disruption of the balance between protein phosphorylation
and dephosphorylation in a manner similar to phorbol esters and okadaic
acid. Phorbol esters, which bind to and activate PKC, and okadaic acid,
which binds to and inhibits protein phosphatases-1 and -2A, are among the
most potent tumour promoting agents known.  Oxidants in CSC lead to an
increase in PKC activity and may enhance its oncogenic role. Recent
experiment with mice indicated an increase in nodular metastasis in lungs
three weeks after injection of experimental Lewis lung carcinoma cells
(LLC-cells) treated with polyphenolic agents in CSC. Hydrochinone,
catechol and other components of CS enhanced adhesion of the so called
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LL/2 carcinoma cells to basement membrane components and endothelial
cells, and increased tumour cell invasion and haematogenous metastasis. All
these events could be inhibited by a variety of PKC inhibitors such as
calphostin C, hypericin, chelerythrine, and bisindolylmaleimide. Anti-
oxidant agents such as catalase and SOD were capable of reducing PKC
activity and therefore inhibiting CSC-mediated membrane association and
metastasis by reducing ROS production rate.  In vitro, CSC increases
tumour cell adhesion to endothelial cells and basement membrane, and may
enhance invasion. As a target for both oxidants and antioxidants, redox
modification of PKC activity may play a central and determining role in
tumour promotion and progression. Therefore, redox-regulated PKC activity
may be relevant to carcinogenesis as well as other pathologies caused by
oxidative stress [18, 50, 51].
Protein kinase A (PKA) for instance shows an influence on invasive and
metastatic characters of tumours by modulating interaction of tumour cells
with extracellular matrix (ECM). PKA levels are said to be more increased
in highly invasive and metastatic than non-metastatic lung cancer cells. An
increase in PKA activity leads to decrease in tumour cell adhesion to some
ECM components (collagen I, vitronectin, and laminin) and may therefore
facilitate dissemination of tumour cells [86]. Some malignant cells, such as
in breast cancer, express CD44 receptor that can bind to hyaluronan, an
ECM component. The receptor-ligand complex may lead to PKA mediated
signal transduction, resulting in rise in intracellular calcium and cyclic
AMP; and this ends up with activation of actin cytoskeletal organisation and
increases metastatic potential by enhancement of movement of malignant
cells along hyaluronan rich surfaces [70,132]. Via phosphorylation of
cytoskeletal subunits and associated proteins such as vimentin, an
intermediate ECM protein, PKA may disrupt the filamentous cytoskeletal
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architecture and influence the cellular morphology. It has been shown in an
experiment that Lewis lung carcinoma cells (LLC-cells) with increased PKA
activity have reduced levels of polymerized actin, tubulin, and vimentin, and
show increased tendency to dislodge, move and invade.  Transfection of
LLC-cells to express PKA Cα subunit was associated with increased
metastatic, invasive, and recurrence potential of the previously non-motile,
non-metastatic cells. When PKA was blocked, highly motile metastatic
LLC-cells lost their motility and invasiveness by acquiring more stability in
cytoskeletal organisation. On the other hand, the PKA-dependent motility by
non-metastatic LLC-cells became increased when dephosphorylation
reactions were blocked with the protein phosphatase-1 and -2A inhibitor
okadaic acid [154,155]. Inhibition of PKA activity in cells with PKA-
dependent motility may therefore indicate a critical measure in therapeutical
intervention against metastasis in future.
Apart from protein kinases C and A, oxidants exposure also increases the
activity of a variety of protein kinases involved in mitogenesis such as
protein tyrosine kinases, c-jun N-terminal kinases and mitogen-activated
kinases (MAPKs). Oxidative stress activates redox-sensitive transcription
factors such as activator protein-1 (AP-1) and nuclear factor kappaB (NF-
% DQG LQGXFHV WKH SURWRRQFRJHQHV Fjun, c-fos, and c-myc [3,124].
Oxidants and nicotine can activate extracellular signal-regulated kinase
(ERK). Experimentally, upregulation of the expression of this MAPK
isotype has led to overexpression of the bcl-2 protein and inhibition of
apoptosis in lung cancer cells [57]. Mediated by nicotinic receptors, nicotine
also has shown to inhibit down-regulation of PKC and ERK2 by anticancer
agents and hence suppress apoptosis [87]. Nicotine therefore may act as a
tumour promoter and affect cancer therapy. Subsequently, studies have
shown that oxidants can inactivate protein tyrosine phosphatases by
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oxidizing their active site cysteine residues. This leads to an upregulation of
tyrosine phosphorylated proteins and hence increased growth-promoting
effects. The effect of oxidative stress on tyrosine phosphorylation seems to
be due to initiation of signals by protein tyrosine kinases and loss of control
by protein tyrosine phosphatases. The tyrosine protein phosphorylation will
then influence cellular events such as growth, death, and differentiation
[128]. Therefore, oxidation and phosphorylation represent alternative
mechanisms for stimulating cellular responses relevant to the process of
tumour promotion, invasion, and metastasis.
(b) Extracellular matrix changes and cytoskeletal modification
Metastasis is an important characteristic of malignant tumours and provides
a great obstacle to cancer cure. The mechanisms involved in metastatic
spread are not fully clarified yet. However, increasing evidence shows that
metastasis requires alterations in the surrounding extracellular matrix
(ECM), as well as cytoskeletal modification for adhesion, migration, and
extravasation of metastatic cells. Whereas molecular events necessary for
cytoskeletal change include alterations in expression of cell adhesion
molecules which interfere with other neighbouring cells or ECM, changes in
properties of ECM itself may also influence movement of neoplastic cells
from their in situ position. Alterations in the ECM may be due to changed
biosynthesis of extracellular matrix components, or imbalance between
molecules involved in the break-down (proteinases) and maintenance
(antiproteinases) of the ECM. The role of matrix metalloproteinases
(MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in metastatic
phenomenon continues to increase the interest of many scientists all over the
world. Under physiological state, MMPs and TIMPs exist in equilibrium.
Factors associated with an increase in activity of MMPs will lead to an
imbalance between MMPs and TIMPs and may result in increased
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degradation of the ECM and facilitate tumour growth, invasion and
metastasis [27].  Cigarette smoke extract has shown to cause both, a
decrease in biosynthesis of collagen type I and III, as well as an increase in
the expression of MMPs (e.g. MMP-1, MMP-2, and MMP-3). Since radical
scavengers such as ascorbic acid and α-tocopherol can prevent the CS-
induced expression of MMPs, oxidative stress caused by CS seems to play a
critical role in these processes [98,152]. However, metastatic processes
might involve various complex molecular and biochemical pathways.
The role of PKA in cytoskeletal modification and its impact in the processes
involving metastasis and invasion of tumour cells has previously been
explained. Cytoskeleton can also indirectly affect metastatic properties of
tumour cells through its association with intercellular adhesion molecules.
Several studies have indicated the role of endothelial cell adhesion
molecules in the adherence and penetration of blood vessel wall by tumour
cells, allowing them to disseminate and colonize their metastatic sites. For
example, E-cadherins can interact with the actin cytoskeleton through
linkage proteins. Malignant cells express endothelial cell adhesion
molecules; and this expression is said to be modulated by cytokines.
Intergrins on tumour cells bind receptors on endothelial cells such as
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule (V-CAM). Tumour cell proteoglycans recognize and bind platelet
endothelial cell adhesion molecule-1 (PECAM-1) [25]. All these effects
may play an important role in the processes of metastasis and hence tumour
progression.
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(c) Mucin glycoprotein genes
The dysregulation of mucin expression in different cancer types is well
known. Aberrant expression of mucin (glycosilation, underglycosilation,
and overexpression of mucin peptides) and mucin-related antigens has been
reported and considered to be a poor survival factor in adenocarcinomas
arising from various organs such as colon, pancreas and breast cancer.
Several genes which encode distinct mucin core peptides have been
identified so far (e.g. muc-1, muc-2, muc-3, muc-4, muc-5b and muc-5ac).
The expression of mucin in cancer cells, as demonstrated in an in vitro
study, can decrease tumour cell aggregation, promote tumour cell invasion,
block lymphocyte targeting and therefore facilitate metastasis by escape
from immunological surveillance. The membrane-associated muc-1 gene for
instance produces a corresponding muc-1 protein that prevents cellular
adhesion by masking certain adhesion molecules on cell surfaces.  The
abundance of siliac acid residues in mucin (sialomucin) increases the
antiadhesive effect of tumour cells by making the glycans more bulky and
thus contributing to the rigidity of mucoprotein; and gives the glycoprotein a
strong negative charge that causes repulsion of cell surfaces. The muc-1
protein strongly interferes with the function of lymphocyte activated killer
(LAK) cells and allogenic stimmulated cytotoxic T-lymphocytes by
masking cell-surface antigens that are involved in immune recognition
processes. The amount of siliac acid present on the surface of malignant
cells has been correlated with the ability of tumours to metastasize. In
adenocarcinoma cells of colon, this effect was reduced on treatment of the
cells with specific inhibitor of siliac acid. The alteration of siliac acid
expression alters the binding of cancer cells to reticuloendothelial cells
(adherence to E- and P-selectin) and to ECM (less adherence to collagen and
stronger adherence to fibronectin), and can therefore promote metastasis of
cancer cells. The study of Yu et al. [157] has shown a strong association
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between overexpression of sialomucin with overexpression of erb-2
oncoprotein, which is an important negative prognostic factor in many
cancer types. In lung cancer, mucin is particularly expressed in non-small-
cell lung cancer (NSCLC), especially in adenocarcinoma. Results from the
other study of Yu et al. [156] have shown a strong correlation between
smoking habits and mucin gene expression in patients with NSCLC.
Tumours of smokers had higher expression of mucin glycoprotein genes,
especially muc-5b and muc-5ac mRNA. Tumours with overexpression of
mucin gene were associated with early post-operative recurrence, metastasis
and cancer death in NSCLC.
4.3.2 Multidrug resistance (MDR)
(a) Proteinkinase C, P-glycoprotein and other resistance-related
     proteins
Tumour cells may be insensitive to chemotherapeutic agents due to
possession of multidrug-resistant phenotypes. It is well known that resistant
phenotypes can result by exposing normal or neoplastic cells to carcinogens
or antineoplastic drugs [30, 31]. Several proteins (including transport-
associated proteins) are involved in multidrug resistance, among them P-
glycoprotein (P-gp or P-170), multiresistance protein 1, heat shock proteins
(HSPs), glutathione S-transferase-pi (GSTP), thymidylate synthetase (TS),
topoisomerase II (topo-II), lung resistance-related protein (LRP) and
putative regulators of resistance (Fos, Jun and ErbB1). Treatment of MDR
cells with PKC activators is associated with an increased phosphorylation of
P-gp and decreased intracellular drug accumulation and drug sensitivity [28,
29]. On the other hand, induction of MDR can be blocked by PKC inhibitors
such as calphostin C and staurosporin [96,116], showing an evidence that
PKC is involved in regulating activity of P-gp. The involvement of some
PKC isoenzymes (e.g. PKCα) in the MDR phenomenon is believed to be
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due to phosphorylation of serine in P-gp, thereby changing the geometric
equilibrium of the P-gp ATPase and hence its drug-binding functions.
However, recent work has shown that safingol, a lysosphingolipid derivative
which specifically inhibits PKC activity via competitive interaction with the
regulatory phorbol-binding domain of PKC, can inhibit the MDR phenotype
without altering P-gp drug binding [115]. PKC may be more directly
involved in activation of the mdr-1 gene since it has AP-1 binding site in its
promoter region which may interact with PKC. AP-1 binding sites are DNA
sequences at which some proteins such as the c-fos/c-jun complex
specifically bind and thereby affect the transcriptional expression of cellular
genes. PKC may therefore have a functional importance as a stimulator of
the activity of proto-oncogenes such as c-fos and c-jun. The c-fos and c-jun
oncogenes belong to resistance-related proteins in cancers of the lung and
other organs. Other resistance-related proteins such as GSTP and topo-II are
also phosphorylated by PKC. The promoter region of the GST gene contains
an AP-1 binding site, and may therefore be regulated by the oncogenes c-fos
and c-jun. Expression of these proteins has shown to associate with
resistance to doxorubicin in lung cancer. Since PKC seems to play a central
role in the acquired and inherent resistance of human cancers, it might be
helpful to devise new strategical approaches to circumvent drug resistance.
Potential PKC inhibitors such as tamoxifen, cyclosporin A, trifluoperazine,
and chlorpromazine are some of important MDR reversing substances [141].
The role of CS tumour promoters catechol and hydroquinone as well as
oxidants in PKC activation has previously been explained. This suggests
that cigarette smoking may be involved in causing resistance of tumour cells
to some anticancer drugs, among them doxorubicin, and cisplatin.
Moreover, a study [140] could show that lung carcinomas of smokers
express LRP more frequently compared to those of non-smokers. In this
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study, a correlation was found between LRP expression and resistance to
doxorubicin in patients with non-small-cell lung cancer. It was also
demonstrated in this study that a relation of borderline exists between the
patients' smoking habits and LRP expression. Lung carcinomas of heavy
smokers were more frequently LRP positive. However, Dingemans et al.
[38] studied 39 normal lung tissues for LRP expression and discovered no
correlation between LRP intensity levels and the number of pack-years
smoked, although a trend was noted for the higher LRP intensity levels in
patients who smoked for more than 10 pack-years.
(b) DNA repair protein O6-alkylylguanine-DNA alkylyltransferase
The DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) is
one of the main determinants of resistance of tumour cells to the cytostatic
effects of O6-alkylguanine-generating alkylating agents. The AGT, encoded
by O6-methylguanine-DNA methyltransferase (MGMT), removes the
methyl group that binds on tumour cell DNA on treatment with alkylating
agents such as cyclophosphamide, and prevents hereby cell apoptosis and
therefore the growth-inhibiting effect of alkylating anticancer agents. The
expression of the human DNA repair protein MGMT is regulated by various
exogenous and endogenous factors. Methionine for example is believed to
participate in MGMT regulation. In a study, up-regulation of MGMT
activity in methionine-dependent phenotypes led to increased cell
proliferation in lung and brain cancer [77]. Increased activity of MGMT is a
natural cellular response against enhanced DNA damage caused by different
cytotoxic agents such as anticancer drugs and CS. It has recently been
shown experimentally that some cell lines in lung cancer react with an
increase in MGMT expression upon exposure to CS. In this experiment, the
CS-induced effect of MGMT activity correlated with the number of
cigarettes smoked. After smoking cessation, MGMT expression could be
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lowered to a significant level. Since an increase in MGMT activity is
associated with an increased repair capacity for O6MG-DNA adducts, CS
may lead to resistance of tumour cells to cytostatic effects of some systemic
anticancer agents. Although MGMT-induced cellular resistance against
anticancer drugs is mainly shown in alkylguanine-generating alkylatig
agents such as cyclophosphamide, combined increase in MGMT and
topoisomerase II (topo-II) activity may expand resistance to anthracycline
derivatives (e.g. daunorubicin and doxorubicin), topo-II inhibitors
(etoposide, teniposide), as well as nitrosoureas (carmustine, lomustine). The
MGMT-induced resistance can partially be reversed by O6-benzylguanine, a
potent inhibitor of MGMT activity [90, 91,103].
(c) Heat shock proteins
Heat shock proteins (HSPs) are a family of stress proteins which are
expressed during severe forms of stress and inflammation.  It is believed that
HSPs are expressed during inflammation in order to protect cells against
oxidative damage. Upregulation of HSPs is therefore a natural response of
cells towards stress-stimuli caused by various factors such as anticancer
therapy and CS constituents. A number of HSPs have been identified so far
and are believed to play important role in lung cancer and during
inflammatory processes in the lung [19]. The HSP70 family belongs to the
most abundantly investigated HSPs. Upon oxidative stress and
inflammation, upregulation of HSP70 occurs in both, normal and neoplastic
cells. Smoking, which is associated with oxidative inflammatory processes
and hypoxic conditions in the lung, induces also overexpression of HSPs. A
study could demonstrate that in tumours of patients with adenocarcinomas
HSP70 expression correlates with smoking habits and the extent of CS
exposure [138]. In subjects who smoked more than 20 cigarettes per day,
89% of the tumours had a high expression of HSP70. This study shows that
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tumour cells also are highly subjected to oxidative stress by CS. Since HSPs
belong to resistance-related factors in different cancer types [136,139],
overexpression of HSP70 in tumours may render lung cancer cells
insensitive to anticancer therapy. However, more research is needed in this
area.
(d) Oncogene-induced phenotype transitions
Tumour progression from therapy-sensitive to therapy-resistant state has
been demonstrated both in vitro and in vivo, and may involve partial or
complete conversion of SCLC to NSCLC [17, 84]. An important molecular
event responsible for the transition between lung cancer phenotypes is the
activation of ras oncogene. The H-ras oncogene-induced transitions occur
predominantly in the so called biochemical variant SCLC with profound
amplification and expression of c-myc oncogene [8, 83]. Alterations in N-
myc amplified SCLC cell line might involve induction of morphological,
biochemical, and growth properties consistent with NSCLC phenotype [45].
These findings provide important links in studying and understanding
molecular events involved in progression of SCLC. Although CS
constituents such as NNK, as well as CS-induced oxidative stress may
participate in the processes involved in ras oncogene activation, less is
known about its contribution to transitional processes in lung cancer.
Therefore, evaluation of the role of CS in H-ras gene activation and
transitional phenomenon of SCLC to NSCLC is a field of great interest as




Apart from MGMT and other resistance-related factors (P-gp, LRP, HSPs
e.t.c), glutathione (GSH) appears to participate in rendering human lung
cancer cells less sensitive to cytostatic effect of chemotherapeutic agents
such as carmustine [41]. Although acute CS exposure leads to GSH
depletion, high levels of this vital cytoprotective antioxidant have been
frequently observed in broncho-alveolar lavage (BAL) and epithelial lining
fluid (ELF) of chronic smokers [99].
In the figure below, the CS-induced carcinogenesis and underlying
mechanisms possible for tumour progression following prolonged CS
exposure are summarized.
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Fig. 1: Scheme showing in summary the effects of smoking (Carcinogenesis in the
lung and mechanisms possible for tumour progression following prolonged exposure to CS).
DRC = DNA repair capacity; SOD = Superoxide dismutase; UGT = Uridine-5'-diphosphate-
glucuronosyl-transferase. Note that all remaining abbreviated words in the scheme and their
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4.4 Disorders in the surfactant system due to cigarette smoke exposure
Many experimental findings on broncho-alveolar lavage (BAL) have shown
that CS constituents can cause disorders in the surfactant system in the lung
[46, 61]. Cigarette smoking leads to reduction of total amount of surfactant
as inhaled particles in CS are incorporated with a large quantity of surfactant
in phagocytes for their clearance during phagocytosis [58]. The surfactant
incorporated with CS particles gets degraded in phagocytes and may be
expectorated. Surfactant in the alveolar system of the lung is important and
has many functions, among them defence mechanisms, and providing an
adequate alveolar surface tension. The surfactant covers the alveolar
epithelial membrane and provides a barrier which hinders direct contact of
the membrane with particulate air pollutants and infectious agents. Tobacco
smoke is also responsible for the destruction and impaired function of cilia.
Cilia are important structures for the natural clearance mechanism of the air
ways. Reduction of surfactant as well as destruction of cilia due to CS are
therefore important factors for the increased susceptibility to
bronchopulmonary infections and inflammatory processes [75], which, in
turn, predispose the lung to structural changes, leading to chronic air way
diseases. Although type II pneumocytes may constantly be activated to
produce surfactant, the destruction rate due to frequent CS exposure may
exceed its new synthesis. The ability of pulmonary surfactant to influence
wall thickness and diameter of airways might be one of the mechanisms
which influence airway resistance and indicates a possible role of CS-
induced change in quality and/or quantity of surfactant in the pathogenesis
of diseases such as COPD and bronchial asthma [60].
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Important functions of surfactant are again summarized below:
1. Stabilisation of airways by preventing airway film and collapse of air
    walls.
2. Protection of the alveolar membrane from direct contact with air
    particles and microorganisms
3. Involvement in processes of bronchial clearance
4. Modulation of airway wall thickness and airway diameter by regulating
    airway liquid balance
5. Immunomodulatory activity due to suppression of cytokine secretion and
    activation of transcription factors
4.5 Cigarette smoke-induced inflammatory processes in the lung
Cigarette smoke is one of the most important contributors of oxidant
pollutant-induced airways injury. Cigarette smoke induces both acute and
chronic inflammatory response in the respiratory tract. While acute
phlogistic reactions are usually reversible, long lasting pulmonary oxidative
stress may induce irreversible lung lesions such as COPD, emphysema, and
interstitial fibrosis [79]. Early inflammatory response to oxidants and
pollutants in CS is driven by native cells such as alveolar macrophages
(AM) and fibroblasts. AM produce ROS and a wide variety of inflammatory
mediators, among them tumour necrosis factor (TNF) and interleukins (e.g.
IL-1, IL-6 and IL-8). The released cytokines cause, among other things,
airway constriction, and lead to increased vascular permeability. IL-8 and
leukotriene B4 (LTB4) are chemoattractants which lead to cellular
chemotaxis, and therefore enhance recruitment and influx of further
inflammatory cells such as polymorphonuclear leucocytes (PMN). As a
marker of neutrophil influx, high levels of myeloperoxidase (MPO) are
observed during inflammatory processes. Inflammatory response occurs
particularly through upregulation of transcription factors such as AP-1, NF-
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κB and ICAM-1. The inflammatory mediators may secondarily modulate
cellular synthesis of proinflammatory growth factors. While upregulation of
the synthesis of the transforming growth factor-β (TGF-β) occurs through
interaction with transcription factors such as AP-1, the regulatory processes
of the platelet-derived growth factor (PDGF) may involve the presence of
the NF-κB. On the other hand, oxidants-activated PKC, as well as
inflammatory cytokines IL-1β and TNF-α, are involved in the regulation of
activity of the NF-κB [11, 78, 94].
The tumour necrosis factor-α (TNF-α), which is a ubiquitous
proinflammatory cytokine, is recognized as an important mediator of
inflammatory events in the lung. The induction of chronic inflammatory
changes in the lung by TNF-α has been associated with an increase in
defence mechanisms including antioxidants [146]. TNF-α induces oxidative
stress by ROS generation via leakage from the mitochondrial electron
transport system and depletes GSH in human alveolar epithelial and
pulmonary artery endothelial cells [105]. A proposal has been done that the
TNF-α-mediated GSH depletion is due to upstream from the ceramide and
sphingomyelinase pathways, which suggests that a signalling mechanism
might be involved in this event. TNF-α and TGF-β levels are elevated in the
broncho-alveolar lavage fluid (BALF) and sputum of COPD patients [73,
81], suggesting involvement of these pro-inflammatory factors in the
pathogenesis of COPD development.
The multifunctional transforming growth factor-β1 (TGF-β1) modulates
cellular proliferation and induces differentiation and synthesis of ECM
components, including collagens and fibronectin in many types of lung cells
[20]. Through mechanisms involving AP-1, TGF-β1 interferes with the
GSH biosynthesis by modulating expression of γ-glutamylcysteine
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synthetase (γ-GCS), the rate-limiting enzyme in de novo GSH synthesis.
The enzyme γ-GCS consists of a catalytic heavy subunit (γ-GCS-HS) and a
regulatory light subunit (γ-GCS-LS). In human, the promoter (5'-flanking)
regions of both γ-GCS-HS and γ-GCS-LS genes contain a putative AP-1
binding site and an antioxidant response element (ARE) that are necessary
for γ-GCS expression in response to diverse stimuli such as CS-induced
oxidative stress. Differences in ELF GSH in various inflammatory lung
disorders may relate to changes in molecular processes involved in
regulation of GSH synthesis in lung by AP-1 and ARE. In vitro, TGF-β1
downregulates both γ-GCS-HS mRNA and GSH synthesis in human
alveolar epithelial cells and pulmonary artery endothelial cells [5].
Interestingly, in an experiment with animal model, transgenic mice
transfected to overexpress TGF-β1 showed decreased GSH synthesis and
increased susceptibility to oxidant-induced lung injury [44]. Thus, high
levels of TGF-β1 during oxidative stress may be involved in downregulation
of GSH and contribute to CS-induced lung disorders such as COPD. An
important result of an in vitro study showed that GSH in levels normally
found in ELF suppresses fibroblast proliferation [26]. Decrease in GSH
concentrations due to inflammatory processes may therefore have direct
structural and functional consequences in the lung. It follows that oxidative
stress plays an important role in the pathogenesis of a wide variety of lung
diseases, not only through direct damage, but by involvement in molecular
mechanisms which control pulmonary inflammatory and proliferative
processes.
- 42 -
4.6 Cigarette smoking: important factor in the development of chronic
      obstructive pulmonary disease (COPD)
The exact mechanisms by which smokers develop COPD are not very clear
yet. The major paradigms for the pathogenesis of COPD are described in the
proteinase-antiproteinase and oxidant-antioxidant theories. An increasing
amount of research has focused on the proposal that an oxidant imbalance
occurs in smokers and in patients with chronic obstructive pulmonary
disease as part of the pathogenesis of this condition. The reason for this is
obvious since CS, which is the major etiological factor in the causes of
development of COPD, contains a large quantity of oxidants. The traditional
role for oxidants in the pathogenesis of COPD, whether inhaled in form of
CS or released from activated neutrophils, is the inactivation of  the natural
inhibitors of neutrophil elastase, namely α1-proteinase inhibitor (α1-PI) and
secretory leucoproteinase inhibitor (SLPI) [110]. Their role is the
inactivation of excessive neutrophil elastase in the lung, which is liberated
during inflammation and destroys elastin and other components of
extracellular connective tissue matrix. Low serum levels of α1-PI have been
often observed in many smokers with pulmonary emphysema. Oxidant-
induced inactivation of α1-PI and SLPI produces a functional deficiency of
these antiproteolytic defence forces in the airspaces, an event that is thought
to be critical to the proteinase/antiproteinase imbalance that occurs as part of
the pathogenesis of emphysema. However, it has been difficult to prove this
theory in vivo since it is complicated by the presence of other proteinases
and antiproteinases and by the fact that few studies in this field have
controlled for the acute effect of smoking. One study that did assess the
acute effect of smoking on the elastase inhibitory capacity of broncho-
alveolar lavage (BAL) found a small but significant decrease in elastase
inhibitory capacity one hour after smoking a cigarette. However other
studies of chronic cigarette smokers, where the smoking history has been
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controlled, have been inconclusive. The development of antioxidant therapy
must take account of these fundamental molecular mechanisms in the
inflammatory response to cigarette smoke in order to effectively protect the
lung against both injurious and pro-inflammatory effects of oxidative stress
[72, 85].
Glutathione (GSH), a ubiquitous intra- and extracellular tripeptide thiol,
plays an important role in the antioxidant defence mechanisms against
oxidative lung injuries due to free radicals and ROS. The synthesis of GSH
requires the presence of γ-glutamylcysteine synthetase (γ-GCS) and GSH
synthetase as major enzymes, as well as ATP, Mg2+, and amino acids
glycine, cysteine, and glutamate. Its synthesis rate depends on the
controlling activity of the enzyme γ-GCS, the availability of cysteine as a
substrate within the cell, and the feedback inhibitory mechanisms exerted by
GSH itself on γ-GCS [93,113]. In lung, oxidants and inflammatory
responses modulate gene expression of many signalling proteins in GSH
metabolism, including GSH itself and γ-GCS. As previously mentioned,
experimental findings suggest that the promoter (5'-flanking) regions of the
γ-GCS-HS and γ-GCS-LS genes are regulated by putative c-jun
homodimeric complex-AP-1 sequences in human alveolar epithelial cells
and other cell lines [131]. It is also suggested that the transcription factor
1)% SOD\V D UROH LQ PRGXODWLRQ RI γ-GCS-HS [66]. Experimentally,
blocking of activation at the transcriptional site of the γ-GCS-HS promoter
prevents the oxidant- or cytokine-induced increase in γ-GCS-HS
transcription in mouse endothelial and liver cells [134]. At the translational
level, GSH synthesis is inhibited by various inflammatory agents such as
cAMP and intracellular calcium that are released during inflammation.
Various signalling pathways are also suggested to be involved in GSH
synthesis. Investigations have determined that an activation of PKA, PKC,
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and Ca2+/calmodulin-dependent kinase II mediates inhibition of GSH
synthesis. This inhibition of GSH synthesis was directly correlated with the
phosphorylation of γ-GCS-HS on serine and threonine residues in a Mg2+
concentration dependent fashion [127]. Thus, the altering GSH levels during
oxidative stress may be attributed to regulation of γ-GCS-HS activity due to
phosphorylation-dephosphorylation. Both cytosolic and mitochondrial GSH
levels may be affected by various inflammatory processes. TNF-α is known
to deplete cytosolic GSH levels transiently in lung epithelial cells [111].
This depletion is thought to be due to radicals formed in mitochondria
during oxidative stress. Cigarette smoke oxidants and ROS also deplete both
cytosolic and mitochondrial GSH levels in lungs. It has recently been shown
that mitochondrial gene transfer of glutathione reductase (GR) and
overexpression of glutathione peroxidase (GPx) in various cell lines
provided a protection of cells under oxidative stress [4,101].Thus,
mitochondrial GSH might also play an important role in maintaining cellular
antioxidant defence system and cell integrity under conditions of oxidative
stress. Apart from GSH, other local and systemic antioxidant systems are
affected during oxidative stress caused by smoking. In a study [42], an
exposure of gas-phase CS has shown to cause a considerable depletion of
various antioxidants such as ascorbate, urate, ubiquinol-10, α-tocopheral,
and β-carotene. Through reduction of antioxidant capacity, the CS-induced
oxidative stress can therefore lead to lung injury and epithelial permeability
change. Airways obstruction will ultimately develop as a consequence of
chronic recurrent inflammatory processes.
In short, the mechanisms of COPD development in smokers may therefore
be explained in the chronic recurrent inflammatory responses, inactivation
of anti-proteinases, and depletion of antioxidants involved during CS-
induced oxidative stress. The most injurious effects of CS seem to occur
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repeatedly during and immediately after acute cigarette smoking when the
lung is depleted in GSH, since increased GSH levels are found in lungs of
chronic smokers as a protective adaptive mechanism. However, the ability
of individuals to regulate antioxidant defence mechanisms, such as the level
of GSH in response to CS, may be genetically determined. Variations in
these protective responses may, in part, relate to why only 15-20% of
smokers develop COPD [122].Thus, alterations in alveolar and lung GSH
metabolism and other antioxidant systems may play a potential role in the
pathogenesis of COPD and other cigarette-related pulmonary diseases. More
knowledge of the mechanisms of GSH regulation and other antioxidants in
the lung could lead to better strategies in preventive and therapeutic
approaches against oxidative lung inflammation and injury.
There are increasing reports suggesting that majority of cancer patients have
also COPD. Since majority of these patients have long-term smoking
history, the destructive pulmonary processes may involve both, the
emphysematous and nonemphysematous obstruction. The most common
complications of COPD are therefore pulmonary hypertension, cor
pulmonale, and recurrent bronchopulmonary infections. Lung cancer
patients may therefore have a limited survival not only because of the cancer
itself, but also due to complications of the smoking habits. As a result, heart
failure and pneumonia are important causes of death among lung cancer
patients. In addition, impaired lung function due COPD and cancer, as well
as reduced erythropoiesis due to bone marrow suppression during
cytoreductive therapy lead together to a tremendous reduction of tissue
oxygenation. This may play a critical role in the frequently observed
reduction of performance status of patients with advanced lung cancer under
palliative anticancer therapy. Both COPD and performance status are
important prognostic factors. COPD alone can lead to a lowered survival, as
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observed in a study which compared COPD patients to healthy individuals
[135].
While diagnosis of COPD mostly requires examination of objective
parameters such as spirometric lung function tests supported by chest
radiography, its prognosis depends largely on the extent of the obstruction.
The grading is based on the extent of the impaired lung function, observed
on the fall in forced expiratory volume in one second (FEV1% of predicted
value) and/or fall in the ratio of FEV1 to the vital capacity (FEV1/VC %). A
mild COPD is characterised with FEV1 values over 70%; whereas FEV1
values ranging between 50 - 69%, and less than 50%, are regarded as
moderate or severe COPD respectively. This staging has been proposed in a
collective statement of the European Respiratory Society (ERS) [120].
5. Cigarette smoking, nicotine abuse and addiction
Through different ways of communication there is enough information
about the carcinogenic and other disease-causing effects of cigarette
smoking. Although the hazardous impact of tobacco consumption on the
health is now world widely well known, many people are still smoking. This
is because there are different factors which influence the use of tobacco
among different age groups of people. More knowledge about
pharmacological, biological, behavioural and social factors is therefore
needed to evaluate different ways of solving this important public health
problem.
Cigarette smoking is a genuine and complex addiction which can be
compared to use of any one of the other known abused addictive substances
such as heroin, cocaine, opiates, and alcohol. It is nicotine that maintains
tobacco addiction. Nicotine is the key substance for the
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neuropharmacological actions of tobacco smoke and has its effect on
nicotinic cholinergic receptors of the central nervous system (CNS), where it
mediates a number of its actions in the body. Its addictive properties appear
to be mediated largely through stimulation of monoaminergic pathways as it
leads to liberation of catecholamines [15]. It acts on different regions of the
human brain. It can induce limbic cortical activation and an increase in
neuronal activity in distributed brain regions. The same mentioned nicotine-
induced effects are previously identified to participate in the mood-elevating
and cognitive properties of other abused drugs such as opiates, cocaine and
amphetamine [125]. These so called positive effects of nicotine are the
strong reinforcements for tobacco users and play a significant role to their
addiction. Nicotine is a substance with euphoriant and anxiolytic effects. It
increases vigilance and intellectual performance. It is addictive and can
induce pharmacological dependence and tolerance if it is repeatedly
delivered to the bloodstream. It leads to physiological and psychological
dependence, as well as withdrawal symptoms if its consumption is abruptly
reduced or stopped. This contributes significantly to the high relapse rate
upon cessation; although there are also other pharmacological and
nonpharmacological factors of tobacco addiction which interfere with
successful discontinuation [13]. However, the effect of nicotine in the brain
is very complex and not fully understood yet. In the following table, a
comparison of nicotine to other abused drugs is made.
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Table 2:  Comparison of addiction to nicotine and other abused drugs
                                           nicotine   cocaine   heroine     alcohol   caffeine
   - psychoactive                     +        +         +           +             +
     effects
   - drug-reinforced                 +              +         +              +             +
     behaviour
   - compulsive                    +              +         +           +           -/+
     use
   - use despite                    +              +             +           +            -/+
     harmful effects
   - relapse after                    +              +             +           +             -
     abstinence
   - recurrent drug      +              +             +           +             +
     cravings
   - drug tolerance      +              +             +           +            +
   - physical                    +              +             +           +             +
     dependence
   - agonist useful in               +              +          -           +             -
     treating dependence 
Adopted from reference Nr. 13
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6. Effects of smoking cessation
Cigarette smoking is a global health care problem. Repetitive exposure to
nicotine produces neuroadaptation leading to nicotine dependence. The
resulting addiction makes smoking cessation difficult. The effects of
stopping smoking or modification of smoking habits among long-term
smokers are mainly observed in the lungs, air ways and CNS.
(a) Pulmonary effects of smoking cessation
After cessation or more than 25% decrease in the number of cigarettes
smoked, significant improvement in spirometric performance can be
registered even among heaviest smokers with a lifetime smoking history and
poorest lung function [64]. In a study, subjects who stopped smoking
completely had shown significant improvement in lung function one month
after cessation, and continued for as long as half a year, and then remained
stable [23]. Smoking cessation may also lead to structural improvement and
hence amelioration of diffusing capacity of the lung [24]. In addition, other
studies could register a dramatic decrease in respiratory symptoms in those
who stopped smoking, a moderate decrease in those who reduced by at least
25%, and very little or no change in those who did not significantly modify
their smoking habits [76,92]. This suggests that smoking cessation can
prevent lung function from further damage or partly reverse the damaged
lung function.
- 50 -
(b) Nicotine withdrawal syndrome
Upon abrupt stop or cut down of tobacco consumption among nicotine-
addicted patients, psychovegetative reactions may result with manifestation
of withdrawal symptoms of individually different degrees of severity,
depending largely on the extent of addiction of the individual. The majority
of smokers quit with minimal physical withdrawal symptoms. However, all
experience some degree of psychological changes such as restlessness,
increased irritation, fluctuation in mood, aggressiveness, increased anxiety,
cognitive impairments, diminished stress tolerance, sleep disturbances, and
craving for tobacco.  The distinction between physical and psychic
responses is some what artificial and difficult to delineate. However, to
isolate the more physically based symptoms quitters record headache,
dizziness, sweating and difficulties in concentrating. Most of the responses
mentioned could be due to a drop in blood pressure that happens during the
first two to three weeks of nicotine abstinence. Hunger, weight gain,
constipation, probably due to the absence of gastrocolic reflex caused by
CS, and creeping sensations in or beneath the skin due to spasmodic
relaxation of smooth musculature in the peripheral blood vessels have also
been reported [21,33]. All the above mentioned symptoms may lead to an
extra burden to lung cancer patients who are generally already under
immense psychological downcast. In such a situation, the compliance of
patients as well as further disease course (in terms of quality of life) may be
negatively influenced.
To date, the problem of nicotine withdrawal syndrome in smoking cessation
programmes is partly managed by administration of nicotine as replacement
therapy. Nicotine as medication for smoking cessation, and at the same time
prevention of withdrawal syndrome, is currently available as chewing gum,
transdermal delivery patch, inhaler, and nasal spray [14]. Recent
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experimental findings in nicotine kinetics and metabolism may lead to
introduction of novel pharmacological treatments in smoking cessation
programmes. Further clinical analysis is needed to evaluate significance of
other pharmaco-therapeutic approaches of nicotine addiction such as use of
clonidine and antidepressant drugs [39, 47].
However, the exact mechanisms underlying nicotine addiction have to be
more analysed. Many factors for individual differences in initiation,
reinforcing effects, addiction, withdrawal and relapse of tobacco use are still
not fully understood. Therefore, the importance of comparing behavioural,
socio-cultural (environmental), biological, as well as pharmacological
processes in the smoking problem has to be frequently assessed. Factors
such as individual differences in nicotine kinetics and metabolism are some
of important pharmacological processes in susceptibility to nicotine
addiction and likelihood of successful smoking cessation [16]. Hence,
successful management of nicotine addiction requires the use of structured,
multidisciplinary, patient-oriented approach that includes nicotine
replacement and withdrawal therapy, intensive monitoring, and long term
follow-up; otherwise, the cessation rates will still remain very low.
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7. Summary of the theoretical background
Cigarette smoking remains the proven major etiological factor for lung
cancer development as indicated in many epidemiological studies carried
out so far. Cigarette smoke contains a large quantity of pulmonary and
extrapulmonary carcinogens. It is also an important source of reactive
oxygen species, and plays a significant role in oxidative DNA damage and
modulation of a number of biochemical pathways in the lung and other
organs. The carcinogens and oxidative tissue damage are the paradigms of
cigarette smoke-induced development of pulmonary and extrapulmonary
malignant and nonmalignant diseases.
However, lung cancer development is a multifactoral process which requires
carcinogen exposure, genetic and nongenetic factors. Genetic factors may
lead to altered metabolism of carcinogens and mechanisms involved in
repair of tobacco smoke-induced DNA damage, and therefore favour lung
cancer development. Among the important enzymes in metabolism of
cigarette smoke carcinogens are the cytochrome P450 (CYP450) and
glutathione S-transferase (GST) gene products. In determining individual
susceptibility to lung cancer development, CYP450 polymorphisms have
been described in isoenzymes such as CYP2E1 and 2A6, while GST
polymorphisms in isoenzymes such as GSTM1 and GSTP1. Polymorphisms
in DNA repair genes or proteins relevant in lung cancer development have
been described in genes such as the xeroderma pigmentosum
complementary groups (XP), x-ray repair cross-complementary groups
(XRCC), and in the DNA repair protein O6-methylguanine-DNA
methyltransferase (MGMT).
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Regarding patients with pre-existing lung cancer, continuation of cigarette
smoking implies a prolonged exposure of bronchial system and other tissues
or organs to carcinogens and oxidative stress. This may provide a possibility
of inducing further molecular changes in normal, preneoplastic and
neoplastic lung cells, as well as in structures important for tissue integrity.
Early preneoplastic morphological changes may bypass further steps and
progress to invasion. Progressive molecular changes in pre-existing tumours
may give rise to altered phenotypes, aggressive or metastatic characters of
the tumours, leading to important therapeutic and prognostic consequences.
Smoking in lung cancer patients may also lead to development of
nonneoplastic disorders which can influence the disease course and
prognosis of lung cancer patients. Important diseases such as COPD, cardio-
vascular diseases, and recurrent bronchopulmonary infections may play
important role in multimorbidity and reduction of survival expectancy of
lung cancer patients.
The lung of smoking lung cancer patients can be regarded as an organ with a
very high exposure to carcinogenic factors (field cancerization), and
therefore an increased risk for development of (pre)malignant lesions due to
multiple genetic abnormalities caused by cigarette smoke. Smoking in lung
cancer patients induces miscoding multiple DNA adducts of oxidative stress
and of cigarette smoke carcinogens. These miscoding DNA adducts may
undergo neoplastic transformation and progress to second lung tumours.
Many studies have been carried out to investigate the risk of second cancer
development in lung cancer patients. Smoking alone elevates the risk of
second cancer development, but a significant risk increase has been reported
when smoking was combined with treatment modalities such as
radiotherapy and/or chemotherapy, or with family history of cancer.
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Cigarette smoke can also induce modulation of a variety of macromolecules
and signalling pathways and hence influence processes involved in tumour
progression in lung cancer patients. These processes are metastasis,
invasion, recurrence and resistance to therapy. Oxidative stress, whether
induced by cigarette smoke or other factors such as anticancer therapy, can
induce protein kinase-mediated cellular signal transduction and therefore
influence regulation of some cellular events such as mitogenesis, cell
adhesion, apoptosis, angiogenesis and metastasis. These are important
events related to tumour promotion and invasion as shown in many studies
investigated the roles of protein kinase A and C in these processes. The
PKA- and PKC-mediated tumour promotion by oxidants appears due to
disruption of the balance between protein phosphorylation and
dephosphorylation. Via PKA and other mechanisms such as altered
biosynthesis of proteinases and antiproteinases, cigarette smoke-induced
oxidative stress may also influence the extracellular matrix and hence
metastatic processes. Metastasis and recurrence may also be associated with
other factors such as sialation of mucin in lung cancer patients. The
abundance of siliac acid residues in mucin is due to overexpression of mucin
glycoprotein genes. These genes are said to be highly expressed in smokers.
The problem of multidrug resistance (MDR) in the treatment of lung cancer
is well known. If exposed to carcinogens or antineoplastic agents, tumour
cells may possess mulltidrug-resistant phenotypes and be insensitive to
chemotherapy. Some transport-associated proteins such as P-glycoprotein
(P-gp or P-170), heat-shock proteins (HSPs), lung resistance protein (LRP)
and others are involved in multidrug resistance. The P-gp related MDR is
partly due to PKC-mediated protein phosphorylation. Both LRP and PKC
are activated by cigarette smoke constituents. Cigarette smoking can induce
overexpression of HSPs, the DNA repair protein O6-methylguanine-DNA
- 55 -
methyltransferase (MGMT), and if chronic also glutathione (GSH). In
experiments these proteins have shown to cause MDR in lung cancer
patients. However, the cigarette smoke-induced MDR may also involve
more complicated mechanisms than these as shown in some molecular
biology studies that observed H-ras oncogene-induced phenotype transition
of SCLC to NSCLC.
Cigarette smoke is an important factor in causing oxidant pollutant-induced
lung injury. Acute inflammatory reactions are usually reversible, but
prolonged exposure to cigarette smoke may induce irreversible lung lesions.
The inflammatory response to cigarette smoke is driven by native cells such
as alveolar macrophages (AM) and fibroblasts. Inflammatory cells produce
DQXPEHURISURLQIODPPDWRU\IDFWRUVVXFKDV,/V/7V71).1)%DQG
7*) 7KURXJK PHFKDQLVPV LQYROYLQJ SURWHLQDVHVDQWLSURWHLQDVHV
oxidants/antioxidants and GSH metabolism, chronic cigarette smoke-
induced inflammatory processes are believed to be responsible for
development of chronic structural lung disorders such as COPD. Cigarette
smoking causes also disorders in the surfactant system and function of cilia.
Cigarette smoke-induced reduction of surfactant and destruction of cilia are
important factors for increased susceptibility to broncho-pulmonary
infections and inflammatory processes which again predispose the lung to
structural changes, leading to chronic air way diseases.
The hazardous effects of cigarette smoking are world widely known.
However, many people are still smoking as nicotine in cigarette smoke is
addictive. When tobacco consumption is abruptly stopped or cut down,
nicotine-addicted lung cancer patients may show psycho-vegetative
reactions with manifestation of withdrawal symptoms. The nicotine
withdrawal syndrome may cause negative impact on the quality of life of the
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patients, and is therefore the biggest obstacle for smoking cessation.
Nicotine replacement and other therapeutic approaches may improve
smoking cessation results. The benefits of smoking cessation have been
described such as a moderate improvement in lung function, better socio-
environmental integration and decrease in incidences of broncho-pulmonary
symptoms and infections. However, smoking cessation among lung cancer
patients may have more positive effects than these as related to different
known and unknown actions of cigarette smoke in the body.
8. Patients and methods
8.1 Data acquisition and study population
The data of the study population of 302 lung cancer patients (47 women and
255 men) admitted between 1992 and 1998 in the department of pulmology
of Beelitz hospital in Brandenburg (Germany) were obtained by collecting
files and extracting important information for the study. The median age of
the patients was 61 years, with a maximum of 84 and a minimum of 36
years. By the time of data collection, 285 (94.4%) of the patients were dead
and the remaining 17 (5.6%) were not to follow up (censored).
The major criteria of inclusion for the study included histologically
confirmed primary lung cancer (SCLC or NSCLC), advanced disease stages
IIIa, IIIb, and IV (UICC category, corresponding to TNM-classification),
primarily palliative based treatment modalities (chemotherapy, chemo-
radiotherapy), and smoking habits after diagnosis (including smokers and
ex-smokers). Patients who never smoked in their life time (non-smokers) are
not included in this study. Patients with local advanced findings of lung
cancer who were definitely treated with radiotherapy alone are also not part
of this study. The criteria for the evaluation of the prognostic impact of
smoking cessation were based on the overall survival time, and therapy
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results.  Whereas patients' smoking habits after diagnosis of lung cancer was
the major factor for investigation of the prognostic impact of smoking
cessation, other factors such as histology and tumour stage were also
regarded as prognosis influencing parameters. However, gender and age
were not matched.
In this study, there were 4 treatment regimes consisting of chemotherapy,
radiotherapy and chemo-radiotherapy (table 3). 209 (69.2%) patients had got
only chemotherapy, and 93 (30.8%) patients were treated with
chemotherapy and radiotherapy as separate or combined modalities.
Because of factors such as death, therapy withdrawal due to massive tumour
progression, and lost patients' follow-up, not all patients were treated in the
therapy regimes 2, 3, and 4.  While 170 (56.3%) patients dropped out during
the 2nd therapy regime, 268 (88.7%) patients could not be treated in the 3rd
therapy regime. Only 6 (2.0%) patients were treated in the 4th therapy
regime. However, all patients were treated in the 1st therapy regime (therapy
regime 1); so that only the therapy results of the first therapy regime (given
as outcome of therapy regime 1) have been considered in this study. The
following table shows the four therapy regimes and the series in which the
therapy was given.
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Table 3: Therapy series in the 4 different regimes
incidence percent valid percent cumulated percent
validity
                   1000
                   1100
                   1110
                   1111
                   1120
                   1200
                   1210
                   1300
                   2000
                   2100
                   2110
                   2111
                   2300
total
     141
       53
       11
         4
         1
         4
         2
         9
       29
       31
       14
         2
         1
     302
   46,7
   17,5
     3,6
     1,3
     0,3
     1,3
     0,7
     3,0
     9,6
   10,3
     4,6
     0,7
     0,3
 100,0
       46,7
       17,5
         3,6
         1,3
         0,3
         1,3
         0,7
         3,0
         9,6
       10,3
         4,6
         0,7
         0,3
     100,0
          46,7
          64,2
          67,9
          69,2
          69,5
          70,9
          71,5
          74,5
          84,1
          94,4
          99,0
          99,7
        100,0
The first column of the table represents the 4 therapy regimes and the series in which the
therapy was given




It follows from the table above that all patients were treated in the first therapy regime, while
141 patients (1000) + 29 patients (2000) [= 170 patients] were not treated in the 2nd therapy
regime
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The distributions of other important parameters in the study population are
summarized in the tables below. Note that percentages given in tables 4 – 8
refer to the total number of patients in the study population. Disease stages
are given according to UICC category.
Table 4: Parameters of the study population based on diagnosis and
               smoking habits
                     smokers                     ex-smokers                  total             
                           n                                   n                             n
sclc               50  (16.5%)                57  (18.9%)                107  (35.4%)
nsclc             104 (34.4%)               91  (30.1%)                195  (64.6%)
total             154 (51.0%)               148 (49.0%)                302 (100.0%)
sclc:
 small-cell lung cancer (= SCLC)
nsclc:
 non-small-cell lung cancer (= NSCLC)
Table 5: Parameters of the study population based on sex and smoking
               habits
                      smokers                      ex-smokers                total
                           n                                   n                            n
females         22   (7.3%)                 25  (8.3%)                  47 (15.6%)
males            132 (43.7%)              123 (40.7%)                255 (84.4%)
total             154 (51.0%)               148 (49.0%)                302 (100.0%)
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Table 6: Histology distribution of patients in the study population based on
               sex and smoking habits
                                      smokers             ex-smokers           total
females                         n = 22                  n = 25                  n = 47
squamous-cell ca.          4   (1.3%)            2    (0.7%)            6    (2.0%)
adeno-ca.                       8   (2.6%)            5    (1.7%)           13  (4.3%)
large-cell ca.                  -   (0.0%)             3    (1.0%)           3   (1.0%)
sclc                               10 (3.3%)             15 (5.0%)             25 (8.8%)
males                            n = 132                n = 123                n = 255
squamous-cell ca.          40 (13.2%)           45(14.9%)           85 (28.1%)
adeno-ca.                       36 (11.9%)          28  (9.3%)           64 (21.2%)
large-cell ca.                  16  (5.3%)            8   (2.6%)           24   (7.9%)
sclc                                40 (13.2%)          42 (13.9%)           82 (27.1%)
total                              n = 154                n = 148               n = 302
squamous-cell ca.          44 (14.5%)           47 (15.6%)          91  (30.1%)
adeno-ca.                      44 (14.5%)           33 (11.0%)          77  (25.5%)
large-cell ca.                 16   (5.5%)           11  (3.6%)           27    (8.9%)
sclc                               50 (16.5%)           57 (18.9%)          107 (35.4%)
The histology distribution in the study population is once again shown in the
diagram below.
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Figure 2: Histogram showing histology distribution in the study population
h i s t o l o g y




























Table 7: Disease stage distribution of patients in the study population
               based on sex and smoking habits
                                  smokers                ex-smokers         total
females                      n = 22                  n = 25                 n = 47
stage IIIa                    2  (0.7%)             1  (0.3%)             3    (1.0%)
stage IIIb                    1   (0.3%)            5  (1.7%)             6    (2.0%)
stage  IV                    19 (6.3%)             19 (6.3%)            38 (12.6%)
males                         n = 132                n = 123               n = 255
stage IIIa                    18 (5.9%)            37 (12.3%)          55   (18.2%)
stage IIIb                    7   (2.3%)            11  (3.6%)           18    (5.9%)
stage  IV                    107 (35.4%)         75 (24.8%)          182 (60.2%)
total                           n = 154                n = 148               n = 302
stage IIIa                    20 (6.6%)            38 (12.6%)          58   (19.2%)
stage IIIb                    8  (2.6%)             16   (5.3%)          24    (7.9%)
stage  IV                    126 (41.7%)         94 (31.1%)          220 (72.8%)
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Table 8: Histology distribution of patients in the study population based on
               sex and disease stage
                               stage  IIIa      stage IIIb      stage  IV        total
females                   n = 3            n = 6            n = 38             n = 47
squamous-cell ca.    -  (0.0%)      1  (0.3%)      5   (1.7%)        6   (2.0%)
adeno-ca.                1  (0.3%)      2  (0.7%)      10 (3.3%)        13 (4.3%)
large-cell ca.            -  (0.0%)      1  (0.3%)      2  (0.7%)         3   (1.0%)
sclc                         2  (0.7%)      2  (0.7%)      21 (6.9%)        25 (8.3%)
males                     n = 55           n = 18           n = 182           n = 255
squamous-cell ca.   29 (6.9%)      5   (1.7%)     51 (16.8%)      85 (28.1%)
adeno-ca.                8  (2.6%)      4  (1.3%)      52 (17.2%)      64 (21.1%)
large-cell ca.           3  (1.0%)      1  (0.3%)      20  (6.6%)       24   (7.9%)
sclc                         15(4.9%)      8  (2.6%)      59 (19.5%)      82 (27.0%)
total                       n = 58           n = 24           n = 220           n = 302
squamous-cell ca.   29 (9.6%)      6  (2.0%)      56 (18.5%)      91  (30.1%)
adeno-ca.                9  (2.9%)      6  (2.0%)      62 (20.5%)      77  (25.4%)
large-cell ca.           3  (1.0%)      2  (0.7%)      22 (7.3%)        27    (9.0%)
sclc                         17 (5.6%)     10 (3.3%)     80 (26.4%)      107 (35.4%)
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Table 9: Histology, smoking habits and disease stage in the study
               population
histology
                                             stage
smoking habits: stage IIIa  stage IIIb  stage IV    total
sclc smokers:                  6               2            42             50
ex-smokers:             11             8            38             57
total                         17             10          80           107
squamous-cell ca. smokers:                  9               3            32             44
ex-smokers:             20             3            24             47
total                         29             6            56             91
adenocarcinoma smokers:                  3               2            39             44
ex-smokers:             6               4            23             33
total                         9               6            62             77
large-cell ca. smokers:                  2               1             13           16
ex-smokers:             1               1             9             11
total                         3               2            22            27
total                                 58             24         220           302
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Table 10: Distribution of patients in terms of smoking habits after
                 diagnosis and the outcome of therapy regime 1
smoking habits
        outcome of therapy regime 1
     p             sd             pr             cr    total
ex-smokers:
   -number
   -% of outcome of
    therapy regime 1
smokers:
   -number
   -% of outcome of
    therapy regime 1
   48            20             69             11
   45.7         55.6          46.9          78.6
   57            16             78               3
   54.3         44.4          53.1          21.4
  148
    49.0
   154
     51.0
total
   -number
   -% of outcome of
    therapy regime 1
   105          36             147           14
   100.0     100.0          100.0       100.0
   302
   100.0
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Table 11: Distribution of patients in groups (cigarette groups) in terms of
                 number of cigarettes smoked per day after diagnosis  and the
                 outcome of therapy regime 1
cigarette groups
 outcome of therapy regime 1
    p          sd          pr         cr   total
(ex-smokers)
 0 /d :          - number
                   - % of outcome of
                     therapy regime 1
(smokers)
1 – 10 /d:    - number
                   - % of outcome of
                     therapy regime 1
11 – 20 /d:  - number
                   - % of outcome of
                     therapy regime 1
> 20 /d:       - number
                   - % of outcome of
                     therapy regime 1
  48         20          69        11
  45.7      55.6       46.9     78.6
  23           8           51         3
  21.9      22.2        34.7     21.4
  25           8           22
  23.8      22.2        15.0
    9                          5
    8.6                       3.4
 148






    4.6
total            - number
                   - % of outcome of
                     therapy regime 1
105         36        147         14
100.0    100.0     100.0     100.0
302
100.0
p = progression       sd = stable disease        pr = partial remission       cr = complete remission
Note that the percentages given in the tables 10 and 11 in different columns of the outcome of
therapy regime 1 refer to the total number of patients with the same therapy result.
- 67 -
Table 12: Distribution of incidences of accompanied patients' heart
                 diseases
incidence  percent valid percent cumulated
  percent
valid:
  heart insufficiency
  arrhythmia
  vitia
  heart insufficiency
  + arrhythmia
  heart insufficiency
  + vitia
  heart insufficiency





       50
         8
         2
       11
         1
         1
       73
     229
     302
   16,6
     2,6
     0,7
     3,6
     0,3
     0,3
   24,2
   75,8
 100,0
      68,5
      11,0
        2,7
      15,1
        1,4
        1,4
    100,0
     68,5
     79,5
     82,2
     97,3
     98,6
   100,0
Table 13: Distribution of incidences of accompanied patients'
                 non-malignant pulmonary diseases
incidence percent valid percent cumulated




  copd + tuberculosis





      89
        2
        1
        1
      93
    209
    302
   29,5
     0,7
     0,3
     0,3
   30,8
   69,2
 100,0
       95,7
         2,2
         1,1
         1,1
     100,0
     95,7
     97,8
     98,9
   100,0
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Table 14: Distribution of incidences of death causes in the study population
incidence percent valid percent cumulated
  percent
valid:
  lung cancer
  pulmonary embolism
  heart failure






    285
        6
        6
        2
        1
        1
        1
    302
   94,4
     2,0
     2,0
     0,7
     0,3
     0,3
     0,3
 100,0
      94,4
        2,0
        2,0
        0,7
        0,3
        0,3
        0,3
    100,0
     94,4
     96,4
     98,3
     99,0
     99,3
     99,7
   100,0
copd: chronic obstructive pulmonary disease (COPD)
Table 12 shows that at least 50 (68.5%) of the total 73 patients who were
registered to have different heart diseases had heart insufficiency caused by
factors other than vitia and/or arrhythmia. The causes of heart insufficiency
among these 50 patients may therefore be coronary artery disease,
hypertensive heart disease, non-classified cardiomyopathy, and other
diseases. Table 13 reveals COPD to be found in most of 93 patients who
were registered to have different accompanied non-malignant pulmonary
diseases. However, as shown in table 14, lung cancer itself remains to be the
major cause of death of patients in the study population as it caused the
death of 285 (94.4%) patients.
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8.2 Statistical data analysis
The statistical data analysis was done using the statistical packet for social
sciences (SPSS). Life table analysis for censored data according to Kaplan
and Meier was used in different groups of patients for investigation of
relationship of smoking status (smokers / ex-smokers) to the overall survival
time. Censoring was performed for patients who were lost to follow-up.
Statistically, a value of p less than 0.05 was considered to be significant.
The correlation between smoking status and therapy results (outcome of
therapy regime 1) was statistically evaluated by using Chi-Square test
according to Pearson. A p value less than 0.05 was considered to be
statistically significant.
9. Results
9.1 Overall survival time
Determinations of the relationship of smoking cessation to the overall
survival time were done for the group with all patients in the study
population (total study population), as well as for different groups formed
by matching histology and/or disease stage as prognosis influencing factors.
The Kaplan-Meier method of determining estimated survival functions for
the factor smoking (smokers / ex-smokers) was used for the total study
population and for every group of patients in the study population. However,
only Kaplan-Meier graph for the total study population is illustrated in this
work.
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Fig. 3: Example of Kaplan-Meier graph showing estimated survival
            functions for the factor smoking (smokers / ex-smokers) in
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- Ex-smokers:
  Number of Cases: 148             Censored: 9 (6.08%)                 Events: 139
           Survival Time (in days)   Standard Error    95% Confidence Interval
  Mean:           296                               27                          (243;  348)
  Median:        240                               21                          (199;  281)
- Overall survival analysis for the factor Smoking in the total study
   population
                       Total  Number Events  Number Censored  Percent Censored
  Smokers:       154             146                        8                         5.19
  Ex-smokers:  148             139                        9                         6.08
  Overall:         302             285                        17                       5.63
- Test statistics for equality of survival distributions for the factor
   Smoking
                                Statistic                     df       Significance
  Log Rank                  7.49                      1                         .0062
  Breslow                    8.12                      1                    .0044
  Tarone-Ware            8.37                      1                              .0038
All results (referred to p - values) of the statistical analysis of the effect of
smoking cessation on the overall survival time in different groups in the
study population are put together in the table below.
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Table 15: Results of the analysis of the effect of smoking cessation on the
                 overall survival time
                                            histology
  sclc      squamous-cell ca.   adenoca.      large-cell ca.   total
stage (UICC)
           IIIa
           IIIb
           IV
           total
                                            (p values)
0.5436       +0.5914           +0.8153        0.2253      +0.8088
(s)   0.6939          0.3209       0.3173      (s)
0.4027       0.3013          0.1992       0.3070      (s)
0.0788       0.2796          (s)   0.1207      (s)
The p value obtained from the group of total patients with non-small-cell lung cancer
(NSCLC) was V
(s)  =  p value statistically significant
  ZLWKDVWDWLVWLFDOO\VLJQLILFDQWGLIIHUHQFHH[VPRNHUVKDGORQJHUPHGLDQVXUYLYDOWKDQ
           smokers
  =  with a statistically non-significant difference, ex-smokers had longer median survival
          than smokers
  +  =  with a statistically non-significant difference, smokers had longer median survival than
           ex-smokers
Detailed description of the results of the overall survival time
Total patients in the study population
In the total number of 302 patients in the study population there were 154
(51.0%) smokers and 148 (49.0%) ex-smokers. Without considering other
prognosis influencing factors such as disease stage as well as histology, the
overall survival time of smokers in the total study population differed
statistically significant (p = 0.0062; log rank) from that of ex-smokers. The
median survival of smokers was 180 +/- 21 days, and that of ex-smokers
was 240 +/- 21 days.
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Histology as prognosis influencing factor:
(i) Total patients with small-cell lung cancer
There were 107 patients with small-cell lung cancer in the study population,
of which 50 (46.7%) patients were smokers and 57 (53.3%) patients were
ex-smokers. The overall survival time between smokers and ex-smokers in
patients with small cell lung cancer did not show statistically significant
difference (p = 0.0788). The median survival of smokers was 258 +/- 20
days, and that of ex-smokers was 284 +/- 28 days.
(ii) Total patients with non-small-cell lung cancer
There were a total of 195 patients with non-small-cell lung cancer, of which
104 (53.3%) patients were smokers and 91 (46.7%) patients were ex-
smokers. There was a statistically significant difference (p = 0.0489; log
rank) in the overall survival time between smokers and ex-smokers in
patients with non-small cell lung cancer. The median survival of smokers
was 151 +/- 21 days, while that of ex-smokers was 181 +/- 22 days.
- Patients with squamous-cell carcinoma
There were 91 patients with squamous-cell carcinoma in the study
population. 44 (48.3%) patients were smokers and 47 (51.7%) patients were
ex-smokers. There was no statistically significant difference (p = 0.2796) in
the overall survival time between smokers and ex-smokers in patients with
squamous cell carcinoma. The median survival of smokers was 146 +/- 38
days, and that of ex-smokers was 193 +/- 38 days.
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- Patients with adenocarcinoma
Patients with adenocarcinoma in the study population were 77, of which 44
(57.2%) patients were smokers and 33 (42.8%) patients were ex-smokers.
The median survival of smokers with adenocarcinoma was 159 +/- 19 days,
and that of ex-smokers was 245 +/- 67 days. This result showed a
statistically significant difference (p = 0.0439; breslow) in the overall
survival time between smokers and ex-smokers in this group.
- Patients with large-cell carcinoma
27 patients in the study population had large-cell carcinoma, of which 16
(59.3%) patients were smokers and 11 (40.7%) patients were ex-smokers.
No statistically significant difference (p = 0.1207) in the overall survival
time was found between smokers and ex-smoker in patients with large-cell
carcinoma. The median survival of smokers was 115 +/- 14 days, and that of
ex-smokers was 154 +/- 36 days.
Disease stage as prognosis influencing factor:
- Patients with disease stage IIIa
There were 58 patients with disease stage IIIa in the study population, of
which 20 (34.5%) patients were smokers and 38 (67.5%) patients were ex-
smokers. Smokers and ex-smokers with disease stage IIIa showed no
statistically significant difference in the overall survival time (p = 0.8088).
Smokers had a median survival of 311 +/- 17 days, and ex-smokers had a
median survival of 293 +/- 39 days.
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- Patients with disease stage IIIb
There were 24 patients with disease stage IIIb in the study population, of
which 8 (33.3%) patients were smokers and 16 (76.7%) patients were ex-
smokers. Patients with disease stage IIIb showed statistically significant
difference (p = 0.0264; log rank) in the overall survival time between
smokers and ex-smokers. While the median survival of smokers was 69 +/-
13 days, ex-smokers lived longer with the median survival of 253 +/- 59
days.
- Patients with disease stage IV
There were 220 patients with disease stage IV in the study population, of
which 126 (57.3%) patients were smokers and 94 (42.7%) patients were ex-
smokers. The overall survival time of smokers with disease stage VI
differed statistically significant (p = 0.0378; tarone-ware) from that of ex-
smokers. Smokers had a median survival of 174 +/- 19 days, and ex-
smokers had a median survival of 209 +/- 23 days.
Histology and disease stage combined as prognosis influencing factors:
- Patients with small-cell lung cancer in disease stage IIIa
There were 17 patients with small-cell lung cancer in disease stage IIIa in
the study population, of which 6 (35.3%) patients were smokers and 11
(74.7%) patients were ex-smokers. Patients with small-cell lung cancer in
disease stage IIIa did not show statistically significant difference (p =
0.5436) in the overall survival time between smokers and ex-smokers. The
median survival of smokers was 302 +/- 39 days, and that of ex-smokers
was 340 +/- 63 days.
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- Patients with small-cell lung cancer in disease stage IIIb
There were 10 patients with small-cell lung cancer in disease stage IIIb in
the study population, of which 2 (20%) patients were smokers and 8 (80%)
patients were ex-smokers. Patients with small-cell lung cancer in disease
stage IIIb showed a statistically significant difference (p = 0.0209; breslow)
in the overall survival time between smokers and ex-smokers. The median
survival of smokers was 27 days, and that of ex-smokers was 416 +/- 213
days. However, this result should be taken with reservation since there were
ex-smokers in this group of patients who could survive advanced lung
cancer for more than two years. This has surely affected the result in favour
of ex-smokers.
- Patients with small-cell lung cancer in disease stage IV
There were 80 patients with small-cell lung cancer in disease stage IV in the
study population, of which 42 (56.5%) patients were smokers and 38
(47.5%) patients were ex-smokers. Patients with small-cell lung cancer in
disease stage IV did not show statistically significant difference (p = 0.4027)
in the overall survival time between smokers and ex-smokers. The median
survival of smokers was 255 +/-23 days, and that of ex-smokers was 263 +/-
23 days.
- Patients with squamous-cell carcinoma in disease stage IIIa
There were 29 patients with squamous-cell carcinoma in disease stage IIIa
in the study population, of which 9 (31.1%) patients were smokers and 20
(68.9%) patients were ex-smokers. Patients with squamous-cell carcinoma
in disease stage IIIa did not show statistically significant difference (p =
0.5914) in the overall survival time between smokers and ex-smokers. The
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median survival of smokers was 311 +/- 194 days, and that of ex-smokers
was 165 +/- 46 days.
- Patients with squamous-cell carcinoma in disease stage IIIb
There were 6 patients with squamous-cell carcinoma in disease stage IIIb in
the study population, of which 3 (50%) patients were smokers and 3 (50%)
patients were ex-smokers. Patients with squamous-cell carcinoma in disease
stage IIIb did not show statistically significant difference (p = 0.6939) in the
overall survival time between smokers and ex-smokers. The median survival
of smokers was 93 +/- 22 days, and that of ex-smokers was 153 +/- 74 days.
- Patients with squamous-cell carcinoma in disease stage IV
There were 56 patients with squamous-cell carcinoma in disease stage IV in
the study population, of which 32 (57.2%) patients were smokers and 24
(42.8%) patients were ex-smokers. Patients with squamous-cell carcinoma
in disease stage IV did not show statistically significant difference (p =
0.3013) in the overall survival time between smokers and ex-smokers. The
median survival of smokers was 146 +/- 39 days, and that of ex-smokers
was 209 +/- 38 days.
- Patients with adenocarcinoma in disease stage IIIa
There were 9 patients with adenocarcinoma in disease stage IIIa in the study
population, of which 3 (33.3%) patients were smokers and 9 (66.7%)
patients were ex-smokers. Patients with adenocarcinoma in disease stage
IIIa did not show statistically significant difference (p = 0.8153) in the
overall survival time between smokers and ex-smokers. The median survival
of smokers was 417 days, and that of ex-smokers was 293 +/- 37 days.
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- Patients with adenocarcinoma in disease stage IIIb
There were 6 patients with adenocarcinoma in disease stage IIIb in the study
population, of which 2 (33.4%) patients were smokers and 4 (66.6%)
patients were ex-smokers. Patients with adenocarcinoma in disease stage
IIIb did not show statistically significant difference (p = 0.3209) in the
overall survival time between smokers and ex-smokers. The median survival
of smokers was 69 days, and that of ex-smokers was 181 +/- 145 days.
- Patients with adenocarcinoma in disease stage IV
There were 62 patients with adenocarcinoma in disease stage IV in the study
population, of which 39 (62.9%) patients were smokers and 23 (37.1%)
patients were ex-smokers. Patients with adenocarcinoma in disease stage IV
did not show statistically significant difference (p = 0.1992) in the overall
survival time between smokers and ex-smokers. The median survival of
smokers was 153 +/- 21 days, and that of ex-smokers was 140 +/- 20 days.
- Patients with large-cell carcinoma in disease stage IIIa
There were 3 patients with large-cell carcinoma in disease stage IIIa in the
study population, of which 2 (66.7%) patients were smokers and 1 (33.3%)
patient was ex-smoker. Patients with large-cell carcinoma in disease stage
IIIa did not show statistically significant difference (p = 0.2253) in the
overall survival time between smokers and ex-smokers. The median survival
of smokers was 148 days, and that of ex-smokers was 343 days.
- Patients with large-cell carcinoma in disease stage IIIb
There were 2 patients with large-cell carcinoma in disease stage IIIb, of
which 1 (50%) patient was smoker and 1 (50%) patient was ex-smoker. The
2 patients with large-cell carcinoma in disease stage IIIb did not show
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statistically significant difference (p = 0.3173) in the overall survival time.
The median survival of the smoker was 18 days, and that of the ex-smoker
was 168 days.
- Patients with large-cell carcinoma in disease stage IV
There were 22 patients with large-cell carcinoma in disease stage IV in the
study population, of which 13 (59.1%) patients were smokers and 9 (40.9%)
patients were ex-smokers. Patients with large-cell carcinoma in disease
stage IV did not show statistically significant difference (p = 0.3070) in the
overall survival time between smokers and ex-smokers. The median survival
of smokers was 115 +/- 14 days, and that of ex-smokers was 122 +/- 28
days.
9.2 Outcome of therapy regime 1 (therapy results)
The outcome of therapy regime 1, which can be regarded as the therapy
sensitivity, was objectively measured by considering therapy results
obtained in staging examinations of patients after therapy regime 1. Staging
examinations were carried out using commonly known methods such as
conventional chest radiography, sonography, and computed tomography.
The therapy results are given in tables 10 and 11 as complete remission,
partial remission, stable disease, or progression. The p value obtained from
the Chi-Square test was 0.1010 (statistically not significant). This
calculation was done only for the total study population without adjustment
of patients for histology and/or disease stage. It follows that there is no
statistically significant difference in the outcome of therapy regime 1
between smokers and ex-smokers in the total study population. However,
interesting results were obtained when patients were put in cigarette groups
according to the number of cigarettes smoked per day. These results are
explained and interpreted in the discussion below.
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10. Discussion
The objective of the present study was to determine how discontinuation of
cigarette smoking influences the prognosis of 302 patients with advanced
lung cancer who were under palliative anticancer therapy in the previously
mentioned hospital in Germany. In the study population there were patients
in different advanced disease stages (IIIa, IIIb, IV) and with different lung
cancer histologies (SCLC and NSCLC). All commonly known histologies of
NSCLC, namely squamous-cell carcinoma, adenocarcinoma and large-cell
carcinoma, were found in different patients in the study population. Patients
were treated either with chemotherapy alone, or chemotherapy and
radiotherapy as separate or combined modalities. The survival times and
outcome of therapy regime 1 (therapy results) were separately used as
measures for the prognostic effect of smoking cessation. This retrospective
study was carried out by collecting files of patients and extracting important
information for the study such as smoking status, therapy modality, outcome
of therapy regimes, survival time, histology, disease stage and others.
In this study there were twenty-one different groups of patients formed
(table 15). One group consisted of all patients in the study population (total
study population) without matching histology and/or disease stage. Five
groups were only histology-matched, and three groups were adjusted for
disease stage. Twelve groups were adjusted for both histology and disease
stage. Histology and disease stage were regarded as potential prognosis
influencing factors. In some groups of patients, smoking cessation prior to
beginning of palliative anticancer therapy has shown to have positive
prognostic effect on the overall survival outlook. With a statistically
significant difference, ex-smokers had longer median survival than smokers
in the group with all patients in the study population (p = 0.0062), in the
group of total patients with non-small cell lung cancer (p = 0.0489), in the
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group of total patients with adenocarcinoma (p = 0.0439), in the group of
total patients with disease stage IIIb (p = 0.0264) and IV (p = 0.0378), and
in the group consisting of patients with small-cell lung cancer in disease
stage IIIb (p = 0.0209). All remaining fifteen groups of patients did not
show any statistically significant difference in the overall survival time
between smokers and ex-smokers. However, with the exception of three
groups, namely the group of all patients with disease stage IIIa, the group of
patients with squamous-cell carcinoma in disease stage IIIa, and the group
of patients with adenocarcinoma in disease stage IIIa, ex-smokers had
longer median survival than smokers in twelve of the fifteen groups of
patients. In these three groups, smokers had longer median survival than ex-
smokers. Since ex-smokers had longer median survival than smokers in
disease stage IIIa patients with small-cell lung cancer and large-cell
carcinoma, it is difficult to make a general statement on the prognostic
association between smoking and disease stage IIIa; but a tendency is shown
that the prognosis of patients with less advanced lung tumours may be less
affected by cigarette smoking after diagnosis than that of patients with more
advanced lung tumours.
The above results are therefore consistent with the fact that there are many
determinants of overall survival time apart from histology and disease stage.
Among these determinants are metastatic status, poor performance status,
tumour size, treatment modality, and other prognostic influencing factors
such as anaemia, age and gender. For obtaining more accurate tools for a
rational treatment decision, Wigren et al. [144] identified in a retrospective
study some important determinants of overall survival time in patients with
non-small-cell lung cancer and combined them to a prognostic index. Since
every patient is likely to have one or more prognostic determinants which
differ from those of others, patients can be put into their corresponding
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prognostic groups which may be identifiable as separate prognostic clusters.
The prognostic index, which should be verified by using independent data,
may be useful in daily clinical practice in the future. Nevertheless, the
prognostic factors in the study of Wigren et al. were so strong that
multivariate analysis did not reveal the treatment modality to have any
significant influence on the survival. Therefore, this is an area of further
investigations.
The outcome of therapy regime 1, which reflects the sensitivity of
anticancer therapy, was measured based on the therapy results such as
complete remission, partial remission, stable disease, and progression after a
completed therapy regime 1. The therapy results were obtained by staging
examinations of patients after the above mentioned therapy regime. There
was no statistically significant difference between smokers and ex-smokers
when the outcome of therapy regime 1 was tested for the total study
population. However, majority of patients (78.6%) with complete remission
were ex-smokers (tables 10 and 11). This percentage corresponds to 11 of
the total 14 patients who reached complete remission after a completed
therapy regime 1.  Furthermore, the remaining 3 (21.4%) patients with
complete remission belonged to the group of patients with the lowest daily
cigarette consumption (1 – 10 cigarettes per day). There were no patients
with complete remission from groups of patients with consumption of more
than 10 cigarettes per day. When patients without complete remission after a
completed therapy regime 1 were analysed, interesting results could be
observed. There were 105 patients who experienced tumour progression; 48
(45.7%) patients were ex-smokers and 57 (54.3%) patients were smokers. 36
patients had stable disease, of which 20 (55.6%) patients were ex-smokers
and 16 (44.4%) patients were smokers. However, only 69 (46.9%) patients
from a total number of 147 patients with partial remission were ex-smokers.
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More interesting results were observed in patients who smoked more than
10 cigarettes per day. In a total number of 55 patients who smoked 11 – 20
cigarettes per day, 25 (45.5%) patients had tumour progression, 8 (14.5%)
patients had stable disease, and 22 (40.0%) patients experienced partial
remission. There were 14 patients in the total study population with a daily
consumption of more than 20 cigarettes, of which 9 (64.3%) patients had
tumour progression, and 5 (35.7%) patients had partial remission. Complete
remission, partial remission and stable disease are, to different extent, more
favourable therapy results than tumour progression. The above results
therefore indicate that ex-smokers frequently experience more favourable
therapy results than smokers during anticancer therapy of advanced
malignant lung tumours.
11. Conclusion
Since patients with advanced lung cancer have generally poor prognosis,
identification of prognostic factors is critical for optimising treatment. It is
therefore important to frequently carry out studies with the goal of
identifying new potential prognostic factors that can improve survival and
quality of life of this group of lung cancer patients. The purpose of this work
was therefore to identify whether smoking cessation has a positive impact
on the prognosis of patients with advanced lung cancer. The background of
this work is based on the different effects of cigarette smoke in the body as
indicated in many scientific findings which have previously been described
in details in this work.
This retrospective study consisted of 302 patients with advanced lung cancer
in disease stages IIIa, IIIb and IV. After histologically confirmed diagnosis
of primary lung cancer, 148 (49%) patients quitted from smoking (ex-
smokers), while 154 (51%) patients continued smoking (smokers). After
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palliative treatment of these patients with chemotherapy and/or chemo-
radiotherapy (table 3), the survival times and therapy results were
statistically evaluated. Since histology and disease stage were regarded as
prognosis influencing parameters, the patients' data concerning the overall
survival times were analysed for the total study population and according to
groups which were formed after adjustment of patients for histology and/or
disease stage (table 15).
On analysing the prognostic effect of smoking cessation on the overall
survival time, ex-smokers lived statistic significantly longer than their
corresponding smokers in some of the groups as previously shown in the
discussion. Whereas ex-smokers lived 1 month longer than smokers in the
group of all patients with non-small-cell lung cancer and in the group of all
patients in disease stage IV, smoking cessation could prolong the overall
survival for about 2 months in the total study population, and for about 3
months in the group of patients with adenocarcinoma. A considerable
prolongation of the overall survival of about 6 months could be reached by
ex-smokers in disease stage IIIb.
On analysing the prognostic effect of smoking cessation on the therapy
results, there was no statistically significant difference between ex-smokers
and smokers in the total study population. However, when patients were put
together into groups according to the number of cigarettes smoked per day
(table 11), interesting results could be observed. The results have shown that
only ex-smokers (78.6%) and smokers (21.4%) who smoked a maximum of
10 cigarettes per day could reach complete remission. Furthermore, ex-
smokers (45.7%) less often experienced tumour progression than smokers
(54.3%). In this study, the probability of reaching tumour progression
depended on the number of cigarettes smoked per day and increased
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significantly (64.3%) by a daily consumption of more than 20 cigarettes.
This is consistent with the results of the studies of Dingemans et al. and
Volm et al.[38,140].
The above results conclude therefore that cigarette smoking cessation
among patients with advanced lung cancer under palliative anticancer
therapy has a positive prognostic effect on the overall survival outlook.
Cigarette smoke may render lung cancer cells less sensitive to anticancer
therapy and therefore negatively affect the prognosis of the patients. The
results also suggest that the prognosis of patients with more advanced
tumours, and with NSCLC (especially adenocarcinomas), may be more
negatively affected following prolonged exposure to cigarette smoke, and
therefore insist histology and disease stage to be important prognostic
factors.
As shown in many studies, cigarette smoke interferes with mechanisms
controlling tumour invasion, metastasis, recurrence, and therapy resistance.
These cigarette smoke-induced effects, which involve metabolic pathways
of macromolecules such as protein kinases, resistance-related proteins and
others, may partly be genetically determined and play a central role in
tumour progression and hence determination of the prognostic impact of
smoking cessation. However, many effects of cigarette smoke in human are
unknown and still remain a challenge to the modern medicine. More
research is required in this area for the better understanding of mechanisms
by which cigarette smoke causes various diseases, the expected time interval
in which the diseases can occur, the individual susceptibility to development
of cigarette smoke-induced diseases, and the possible disease promoting and
progressing effects of cigarette smoke. Genetic involvement of effects of
cigarette smoke has partly been described in factors such as polymorphisms
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in enzymes (e.g. CYP450) relevant in metabolism of tobacco carcinogens,
and in genes responsible for repair of cigarette smoke-induced DNA
damage.
I therefore advise that more and larger studies in this area should be carried
out with adjustment of patients for other potential prognostic factors such as
age and gender. However, if smoking cessation in the treatment of lung
cancer gets recognised in the future as positive prognostic factor, any
decision of asking nicotine-addicted lung cancer patients to quit from
smoking should also consider the problems of nicotine withdrawal
syndrome which may have negative impact on the quality of life (quantity
versus quality of life). As already explained in this work, there are different
therapeutic approaches to this problem which can improve smoking
cessation results.
Conclusion (Translation in German Language)
= Zusammenfassung
Die Prognose der Patienten mit fortgeschrittenem Bronchialkarzinom ist im
allgemeinen schlecht. Die Identifizierung von prognostischen Faktoren ist
daher entscheidend für eine Therapieoptimierung. Demzufolge ist eine
häufigere Durchführung von Studien zur Identifizierung neuer potenzieller
prognostischer Faktoren wichtig, um das Überleben und die Lebensqualität
dieser Patientengruppe zu verbessern. Das Ziel dieser Arbeit war deshalb
herauszufinden, ob eine Zigarettenabstinenz einen positiven Einfluss auf die
Prognose der Patienten mit fortgeschrittenem Bronchialkarzinom hat. Der
Hintergrund dieser Arbeit basiert auf der Tatsache, dass der Zigarettenrauch
eine vielfältige Wirkung auf den menschlichen Körper hat. Dies ist in vielen
wissenschaftlichen Studien belegt und in dieser Arbeit detailliert
beschrieben worden.
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Diese retrospektive Studie bestand aus 302 Patienten mit fortgeschrittenem
Bronchialkarzinom in den Stadien IIIa, IIIb und IV. Nach histologischer
Diagnosesicherung eines primären Bronchialkarzinoms haben 148 (49%)
Patienten das Rauchen eingestellt (Ex-Raucher), während die restlichen 154
(51%) Patienten weiterhin geraucht haben (Raucher). Nach palliativer
Behandlung der Patienten mit Chemotherapie und/oder Chemo-
radiotherapie (Tabelle 3), wurden die Überlebenszeiten und
Therapieergebnisse statistisch ausgewertet. Da Histologie und
Tumorstadium als prognosebeeinflussende Parameter betrachten wurden,
wurden die Patienten nach Histologie und/oder Tumorstadium in Gruppen
geordnet. Die Auswertung der Gesamtüberlebenszeiten erfolgte sowohl für
die Gesamtstudienpopulation als auch für die entstandenen
Patientengruppen (Tabelle 15).
Wie es in der Diskussion beschrieben wurde, hat die Analyse der
prognostischen Wirkung von Zigarettenabstinenz auf die
Gesamtüberlebenszeit ergeben, dass die Ex-Raucher in einigen der Gruppen
statistisch gesehen ein erhöhtes Gesamtüberleben haben im Vergleich zu
Rauchern. Während die Ex-Raucher in der Gruppe der Patienten mit nicht-
kleinzelligem Bronchialkarzinom und der Patienten in Tumorstadium IV
jeweils 1 Monat länger als die Raucher lebten, erzielte eine
Zigarettenabstinenz eine Verlängerung des Gesamtüberlebens um 2 Monate
bei den Patienten innerhalb der gesamten Studienpopulation, und um 3
Monate bei den Patienten mit Adenokarzinom. Eine erhebliche
Verlängerung des Gesamtüberlebens um 6 Monate konnte bei den Ex-
Rauchern in Tumorstadium IIIb erreicht werden.
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Die Auswertung der prognostischen Wirkung von Zigarettenabstinenz auf
die Therapieergebnisse hat ergeben, dass es keinen statistisch signifikanten
Unterschied zwischen Ex-Rauchern und Rauchern innerhalb der gesamten
Studienpopulation gibt. Allerdings, nachdem Patienten anhand des täglichen
Zigarettenverbrauchs in Gruppen eingeteilt wurden (Tabelle 11), konnten
interessante Ergebnisse beobachtet werden. Die Ergebnisse haben gezeigt,
dass nur Ex-Raucher (78,6%), und Raucher (21,4%), die maximal 10
Zigaretten pro Tag geraucht haben, eine komplette Remission erreichen
konnten. Des Weiteren kam es bei den Ex-Rauchern (45,7%) weniger oft zu
Tumorprogression als bei den Rauchern (54,3%). In dieser Studie war die
Wahrscheinlichkeit zur Entwicklung einer Tumorprogression von der
Anzahl der täglich gerauchten Zigaretten abhängig. Diese
Wahrscheinlichkeit erhöhte sich signifikant (64,3%) bei täglichem
Verbrauch von mehr als 20 Zigaretten. Das ist übereinstimmend mit den
Ergebnissen der Studien von Dingemans et al. und Volm et al. [38,140].
Die Schlussfolgerung aus den oben genannten Ergebnissen ist, dass eine
Zigarettenabstinenz bei den Patienten mit fortgeschrittenem
Bronchialkarzinom, die sich einer palliativen Antikrebstherapie unterziehen,
eine positive Wirkung auf die Prognose in Bezug auf das Gesamtüberleben
hat. Zigarettenrauch kann die Empfindlichkeit von Lungenkrebszellen auf
antineoplastische Therapie verringern, und dadurch die Prognose der
Lungenkrebspatienten negativ beeinflussen. Ferner deuten die Ergebnisse
darauf hin, dass die Prognose der Patienten mit mehr fortgeschrittenen
Tumoren, und mit nicht-kleinzelligen Bronchialkarzinomen (vor allem
Adenokarzinomen), besonders negativ durch anhaltenden Nikotinabusus
beeinflusst werden kann. Somit sind Histologie und Tumorstadium als
wichtige prognostische Faktoren zu betrachten.
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Wie in vielen Studien gezeigt, mischt sich der Zigarettenrauch mit
Mechanismen, die die Vorgänge wie Tumorinvasion, Metastasierung,
Rezidiv, und Therapieresistenz kontrollieren, ein. Diese Wirkungen, die auf
Einflüsse des Zigarettenrauchs auf die Stoffwechselwege von verschiedenen
Makromolekülen wie Proteinkinasen, resistenz-verwandte Proteine, und
andere zurückzuführen sind, können zum Teil genetisch bedingt sein, eine
zentrale Rolle bei der Tumorprogression spielen, und dadurch die
prognostische Bedeutung der Zigarettenabstinenz bestimmen. Allerdings
sind viele Wirkungen des Zigarettenrauchs bei einem Menschen noch
unbekannt und stellen eine Herausforderung für die moderne Medizin dar.
Mehr Forschung wird in diesem Bereich gebraucht, um die Mechanismen
des Zigarettenrauchs bei der Entstehung einer Vielfalt von Erkrankungen,
den erwarteten Zeitabstand bis zur Entwicklung dieser Erkrankungen, die
individuelle Anfälligkeit für zigaretteninduzierte Erkrankungen, so wie die
möglichen krankheitsfördernden und –fortschreitenden Effekte des
Zigarettenrauchs besser zu verstehen. Genetischer Einfluss der Wirkungen
von Zigarettenrauch wurden zum Teil beschrieben in Faktoren wie
Polymorphismen in Enzymen, die für den Stoffwechsel von
Tabakkarzinogenen (z.B. CPY450) relevant, und in Genen, die für die
Reparatur von durch Zigarettenrauch verursachten DNA-Schäden
verantwortlich sind.
Deshalb weise ich darauf hin, dass mehr und größere Studien in diesem
Bereich, unter Berücksichtigung auf andere potenzielle prognostische
Faktoren wie das Alter und Geschlecht der Patienten, durchgeführt werden
sollten. Falls Nikotinabstinenz in der Behandlung von Lungenkrebs in
Zukunft als positiver prognostischer Faktor anerkannt wird, sollte jede
Entscheidung einer Zigarettenabstinenz bei nikotinabhängigen
Lungenkrebspatienten die Probleme eines Nikotinentzugssyndroms
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berücksichtigen, da diese einen negativen Einfluss auf die Lebensqualität
haben können (Lebensquantität versus Lebensqualität). Wie bereits in dieser
Arbeit erklärt, gibt es zu dieser Problematik verschiedene therapeutische
Möglichkeiten, die die Nikotinentwöhnungsergebnisse verbessern können.
12. References
1. Abou-Seif MA (1996) Blood antioxidant status and urine sulphate and thiocyanate levels
in smokers. Biochem Toxicol 11(3):133-8
2. Amos C.I et al. (1999) Is there a genetic basis for lung cancer susceptibility? Recent
Results Cancer Res151:3-12
3. Amstad P.A et al (1992) Mechanisms of c-fos induction by active oxygen. Cancer Res
52:3952-3960.
4. Arai M et al. (1999) Mitochondrial phospholipid hydroperoxide glutathione peroxidase
plays a major role in preventing oxidative injury to cells. J Biol Chem 274: 49244933
5. Arsalane K et al. (1997) Transforming growth factor-β1 is a potent inhibitor of
glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the
GSH rate-limiting enzyme γ-glutamylcysteine synthetase. Am J Respil: Cell Mol Biol 17:
599-607
6. Asami S et al. (1997) Cigarette smoking induces an increase in oxidative DNA damage,
8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis
18(9):1763-6
7. Baramiya M.G (2000) Aging and carcinogenesis-insufficient metabolic cell repair as the
common link. Gerontology 46:328-332
8. Barr L.F et al. (1996) Cell-substratum interactions mediate oncogene-induced phenotype
of lung cancer cells. Cell Growth Differ 7(9):1149-56
9. Bartsch H et al. (2000) Genetic polymorphism of CYP genes, alone or in combination, as
a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9(1):3-28
10. Bast A et al. (1991) Oxidants and antioxidants: state of the art. Am  J Med 91(suppl
3C):2s-13s
11. Becker S et al. (1996) Stimulation of human and rat alveolar macrophages by urban air
particulates: effects on oxidant radical generation and cytokine production. Toxicol Appl
Pharmacol 141(2):637-48
12. Belinsky SA et al. (1988) Cell specific differences in O6-methylguanine-DNA
methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells.
Carcinogenesis 9(11):2053-8
13. Benowitz N.L (1992) Cigarette smoking and nicotine addiction. Med Clin North Am
76(2):415-37
14. Benowitz N.L (1996) Pharmacology of nicotine: addiction and therapeutics. Annu Rev
Pharmacol Toxicol 36:597-613
15. Benowitz (1999) Nicotine addiction. Prim Care 26(3):611-31
16. Benowitz N.L and Jacob P 3rd (1997) Individual differences in nicotine kinetics and
metabolism in humans. NIDA Res Monogr 173:48-64
17. Bepler G et al. (1987) Characterization of two cell lines with distinct phenotypes
established from a patient with small-cell lung cancer. Cancer Res 47(7):1883-91
18. Blobe G.C et al. (1994) Regulation of protein kinase C and role in cancer biology. Cancer
Metastasis Rev 13(3-4):411-31
19. Bonay M et al. (1994) Expression of heat shock proteins in human lung and lung cancers.
Am J Respir Cell Mol Biol 10 (4):453-61
- 91 -
20. Border W.A and Noble N (1994) Transforming growth factor-β in tissue fibrosis. N Engl
J Med 331:1286-1292
21. Bourlaud I et al. (1992) Pharmacology of nicotine. Rev Mal Respir 9(4):36-74
22. Braun K.M et al. (1998) Immunotoxicology of cigarette condensates: suppression of
macrophage responsiveness to interferon gamma. Toxicol Appl Pharmacol149(2):136-43
23. Buist A.S et al. (1979) The effect of smoking cessation on pulmonary function: a 30-
month follow-up of two smoking cessation clinics. Am Rev Respir Dis 120(4):953-7
24. Buist A.S et al. (1976) The effect of smoking cessation on lung function. Am Rev Respir
Dis 114(1):115-22
25. Bukholm I.K et al. (1998) E-cadherin and α-, β- and γ-catenin protein expression in
relation to metastasis in human breast carcinoma. J Pathol 185:262-266
26. Cantin A. M et al. (1990) Extracellular glutathione suppresses human lung fibroblast
proliferation. Am J Respir: Cell Mol Biol 3: 79-85
27. Chambers A.F and Matrisian L.M (1997) Changing views of the role of matrix
metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260-70
28. Chambers T et al. (1990) PKC phosphorylates P-glycoprotein in MDR human KB
carcinoma cells. J Biol Chem 265 :7679-7686
29. Chambers T.C et al. (1993) Regulation of phorbol ester and protein kinase C inhibitors,
and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phoshorylation
and relationship to drug accumulation in multidrug-resistant human KB cells. Mol
Pharmacol 41:1008-1015
30. Chaudhary P.M and Roninson I.B (1993) Induction of multidrug resistance in human cells
by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632-639
31. Chaudhary P.M and Roninson I.B (1992) Activation of MDR gene expression in human
cells by protein kinase C agonists. Oncol Res 4:281-290
32. Cheng L et al. (1999) Expression in normal human tissues of five nucleotide excision
repair genes measured simultaneously by reverse transcription-polymerase chain reaction.
Cancer Epidemiol Biomarkers Prev. 8(9):801-7
33. Cohen C et al. (1991) Cigarette smoking and addiction. Clin Chest Med 12(4):701-10
34. Cross C.E et al. (1994) Oxidants, antioxidants, and respiratory tract lining fluids. Environ
Health Perspect 102 (suppl 10):185-91
35. Deutsch-Wenzel R.P et al. (1983) Experimental studies in rat lungs on the carcinogenicity
and dose-response relationships of eight frequently occurring environmental polycyclic
aromatic hydrocarbons. J Natl Cancer Inst 71:539-44
36. Doelman C.J.A and Bast A (1990) Oxygen radicals in lung pathology. Free Rad Biol Med
9:381- 400
37. Dube M.F and Green C.R (1982) Methods of collection of smoke for analytical purposes.
Recent Adv Tob Sci 8:42-102
38. Dingemans A.M et al. (1996) Expression of the human major vault protein LRP in human
lung cancer samples and normal lung tissues. Ann Oncol 7:625-630
39. Di Chiara G (2000) The role of dopamine in the behavioural actions of nicotine related to
addiction. Eur J Pharmacol 393(1-3):295-314
40. Divine K.K et al. (2001) The XRCC1 399 glutamine allele is a risk factor for
adenocarcinoma of the lung. Mutat Res 461(4):273-8
41. Egyhazi S et al. (1997) Role of O6- methylguanine-DNA methyltransferase, glutathione
transferase M3-3 and glutathione in resistance to carmustine in a human non-small-cell
lung cancer cell line. Eur J Cancer 33(3):447-52
42. Eiserich J. P et al. (1995) Dietary antioxidants and cigarette smoke-induced biomolecular
damage: a complex interaction. Am J Clin Nutr 62: 14908-15008
43. Esteller M et al. (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA
methyltransferase by promoter hypermethylation is a common event in primary human
neoplasia. Cancer Res. 59(4):793-7
44. Factor V.M et al. (1998) Disruption of redox homeostasis in the transforming growth
factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J BioI
Chem 273: 1584615853
- 92 -
45. Falco J.P et al. (1990) v-rasH induces non-small-cell phenotype, with associated growth
factors and receptors, in a small-cell lung cancer cell line. J Clin Invest 85(6):1740-5
46. Finely T.N (1983) Smoking and lung surfactant. In: Cosmi E.V, Scarpelli E.M;  Eds.:
Pulmonary surfactant system. Amsterdam, New York, Oxyford 297-310
47. Fowler J.S et al. (1998) Neuropharmacological actions of cigarette smoke: brain
monoamine oxidase B (MAO B) inhibition. J Addict Dis 17(1):23-34
48. Gazdar AF (1994) The molecular and cellular basis of human lung cancer. Anticancer Res
14(1B):261-7
49. Godschalk R et al. (2002) Comparison of multiple DNA adduct types in tumour adjacent
human lung tissue: effect of cigarette smoking. Carcinogenesis 23(12):2081-6
50. Gopalakrishna R et al. (1994) Tobacco smoke tumour promoters, catechol and
hydroquinone, induce oxidative regulation of protein kinase C and influence invasion and
metastasis of lung carcinoma cells. Proc Natl Acad Sci 91:12233-12237
51. Gopalakrishna R and Jake S (2000) Protein kinase C signalling and oxidative stress. Free
Radic Biol Med 28(9):1349-61
52. Grimmer G et al. (1988) Contribution of polycyclic aromatic compounds to the
carcinogenicity of sidestream smoke of cigarettes evaluated by implantation into the lungs
of rats. Cancer Lett 43:173-177
53. Grimmer G et al. (1987) Gaschromatographic determination of polycyclic aromatic
hydrocarbons, aza-arenes, aromatic amines in the particle and vapour phase of main-
stream and side-stream smoke of cigarettes. Toxicology Letters, 35:117-124
54. Harley N.B et al. (1980) Polonium-210: a questionable risk factor in smoking related
carcinogenesis. Banbury Report 3: a safe cigarette? Cold Spring Harbor (NY): Cold
Spring Harbor Laboratory;  p. 93104
55. Hecht S.S. (1999) Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst,
91(14):1194-210
56. Hecht S.S and Hoffmann D (1988) Tobacco-specific nitrosoamines, an important group of
carcinogens in tobacco and tobacco smoke. Carcinogenesis 9:875-84
57. Heusch W.L and Maneckjee R (1998) Signalling pathways involved in nicotine regulation
of apoptosis in human lung cancer cells. Carcinogenesis 19(4):551-6
58. Hingenbottam T (1987) Pulmonary surfactant and chronic lung disease. Eur J Respir Dis
Suppl 153:222-8
59. Hiroshima K et al. (1998) Synchronous and metachronous lung carcinomas: molecular
evidence for multicentricity. Pathol Int 84(11):869-76
60. Hohlfeld J et al. (1997) The role of pulmonary surfactant in obstructive airways disease.
Eur Respir J 10(2):482-91
61. Honda Y et al. (1996) Decreased contents of surfactant proteins A and D in BAL fluids of
healthy smokers. Chest 109(4):1006-9
62. Hou S.M et al. (2002) The XPD variant alleles are associated with increased aromatic
DNA adduct level and lung cancer risk. Carcinogenesis 23(4):599-60355
63. Howard D.J et al. (1998) Oxidative DNA damage in mouse heart, liver, and lung tissue
due to acute side-stream tobacco smoke exposure. Arch Biochem  Biophys 352(2):293-7
64. Huang B and Qin H (1995) Changes of lung function in ex-smokers. Chung Hua Yu Fang
I Hsueh Tsa Chih 29(6):354-5
65. Huang J et al. (2002) Clonality of combined tumors. Arch Pathol Lab Med 126(4):437-41
66. Iwanga M et al. (1998) Nuclear factor kappa B dependent induction of gamma-
glutamylcystine synthetase by ionizing radiation in T98G human glioblastoma cells. Free
Radic Biol Med 24: 1256-1268
67. Jassem J et al. (2004) P53 and K-ras mutations are frequent events in microscopically
negative surgical margins from patients with non-small-cell lung carcinoma. Cancer
100(9):1951-60
68. Jeon H.S et al. (2003) Relationship between XPG codon 1104 polymorphism and risk of
primary lung cancer. Carcinogenesis 24(10):1677-81
69. Johnson B.E et al. (1997) Second lung cancers in patients successfully treated for lung
cancer. Semin Oncol (4):492-9
- 93 -
70. Johnson JP (1991) Cell adhesion molecules of the immunoglobulin supergene family and
their role in malignant transformation and progression to metastatic disease. Cancer
metastasis Rev 10:11-12
71. Kawahara M et al. (1998) Second primary tumours in more than 2-year disease-free
survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer
78(3):409-12
72. Kawane H (1999) Smoking as a risk factor for COPD and prognosis after smoking
cessation. Nippon Rinsho 57(9):1959-64
73. Keating S.V.M et al. (1996) Differences in interleukin-8 and tumour necrosis factor-alpha
in induced sputum from patients with chronic obstructive pulmonary disease or asthma.
Am J Respir: Crit Care Med 153:530-534
74. Kelley M.J et al. (1996) Genetic analysis of second primary lung cancers in patients
surviving small-cell lung cancer. Clin Cancer  Res 2(7):1103-5
75. Kletch H and Kummer F (1994) Smoking causes chronic obstructive lung diseases and
increased infections of the respiratory tract. Wien Med Wochenschr 144(22-23):535-40
76. Knudson R.J et al. (1989) The effects of cigarette smoking and smoking cessation on the
carbon monoxide diffusing capacity of the lung in asymptomatic subjects. Am Rev Respir
Dis 140(3):645-51
77. Kokkinakis D.M et al. (1997) Regulation of O6- methylguanine-DNA methyltransferase
by methionine in human tumour cells. Br J Cancer 75(6):779-88
78. Krishna M.T et al. (1998) Toxicological mechanisms underlying oxidant-induced airway
injury. Rev Environ Health 13(1-2):59-71
79. Leuenberger P (1994) Respiratory diseases and oxidants. Schweiz Med Wochenschr
124(4):129-35
80. Liang G et al. (2003) Sequence variations in the DNA repair gene XPD and risk of lung
cancer in a Chinese population. Int J Cancer 105(5):669-73
81. Liu B et al. (1998) Glutathione regulation of neutral sphingomyelinase in tumour necrosis
factor-alpha-induced cell death. J Biol Chem 273:11313-11320
82. Lykkesfeldt et al. (1997) Ascorbic acid and dehydroascorbic acid as biomarkers of
oxidative stress caused by smoking. Am J Clin Nutr 65(4):959-63
83. Mabry M et al. (1988) v-Ha-ras oncogene insertion: a model for tumour progression of
human small-cell lung cancer. Proc Natl Acad Sci USA 85(17):6523-7
84. Mabry M et al. (1991) Transitions between lung cancer phenotypes: implications for
tumour progression. Cancer Cells 3(2):53-8
85. MacNee W (2000) Oxidants / antioxidants and COPD. Chest 117(5 Suppl 1):303S-17S
86. Maier D.G et al. (1996) Protein kinase A regulates Lewis lung carcinoma adherence to
extracellular matrix components and spontaneous metastasis. Clin Exp Metastasis 14:314-
322
87. Maneckjee R, Minna JD (1994) Opioids induce while nicotine suppresses apoptosis in
human lung cancer cells. Cell Growth Differ 5(10):1033-40
88. Martensson J et al. (1989) Glutathione metabolism in the lung: inhibition of its synthesis
leads to lamellar body and mitochondrial defects. Proc Natl Acad Sci USA 86: 5296-5300
89. Martinet Y et al. (1998) Clinical and Biological Basis of Lung Cancer Prevention.
90. Mattern J et al. (1998) Smoking-related increase of O6-methylguanine-DNA
methyltransferase expression in human lung carcinomas. Carcinogenesis 19(7):1247-50
91. Mattern J et al. (1998) O6-methylguanine-DNA methyltransferase activity and sensitivity
to cyclophosphamide and cisplatin in human lung tumour xenografts. Int J Cancer
77(6):919-22
92. McCarthy D.S et al. (1976) Effect of modification of the smoking habit on lung function.
Am Rev Respir Dis 114(1):103-13
93. Meister A and Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
94. Meyer M et al. (1994) Redox control of gene expression by eukaryotic transcription
factors NF-kB, AP-1 and SRF/TCF. In: Pasquier C, Auclair C, Oliver R.Y, Packer L, eds.
Oxidative stress , cell activation and viral infection. Switzerland: Birkhauser Verlag
1994:217-235
- 94 -
95. Misra R.R et al. (2003) Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3,
and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett
191(2):171-8
96. Miyamoto K et al. (1993) Inhibition of multidrug resistance by a new staurosporine
derivative, NA-382, in vitro and in vivo. Cancer Res 53:155-159
97. Montuschi P et al. (2000) Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative
stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 162(3 Pt.
1):1175-7
98. Morimoto Y et al. (1997) Expression of matrix metalloproteinases, tissue inhibitors of
metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers
and cigarette smoke in vivo. Environ Health Perspect 105 Suppl 5:1247-51
99. Morrison D et al. (1999) Epithelial permeability, inflammation, and oxidant status in the
air spaces of chronic smokers. Am J Respir Crit Care Med 159: 473-479
100. Moszczynski P and Slowinski S (1990) Cell-mediated immunity in cigarette smokers.
Wiad Lek 43(3-4): 127-30
101. O'Donovan D et al. (1999) Gene transfer of mitochondrially targeted glutathione
reductase protects H441 cells from t-butyl hydroperoxide-induced oxidant stress. Am J
Respr Cell Mol BioI 20: 256-263
102. Park J.Y et al. (2002) Polymorphisms of the DNA repair gene Xeroderma pigmentosum
group A and risk of primary lung cancer. Cancer epidemiol  Biomarkers Prev 11(10
Pt):993-7
103. Pawlik C.A et al. (1998) Cellular resistance against the novel hybrid anthracycline N-(2-
chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered
topoisomerase II and O6-methylguanine-DNA methyltransferase activities. Oncol Res
10(4):209-17
104. Paz-Elizur T et al. (2003) DNA repair activity for oxidative damage and risk of lung
cancer. J Natl Cancer Inst 95(17):1312-9
105. Phelps D.T et al. (1995) TNF-α induces peroxynitrite-mediated depletion of lung
endothelial glutathione via protein kinase C. Am J Physiol 269 (Lung Cell Mol Physiol
13):L551-L559
106. Prieme H et al. (1998) Effect of smoking cessation on oxidative DNA modification
estimated by 8-oxo-7, 8-dihydro-2'-deoxyguanosine excretion. Carcinogenesis 19(2):347-
51
107. Pryor WA (1997) Cigarette smoke radicals and the role of free radicals in chemical
carcinogenicity. Environ Health Perspect 4:875-82
108. Pryor W.A and Stone K (1993) Oxidants in cigarette smoke: radicals, hydrogen peroxide,
peroxynitrate, and peroxynitrite. Ann N.Y. Acad Sci 686:12-28)
109. Rahman I et al. (1996) systemic oxidative stress in asthma, COPD, and smokers. Am J
Respir Crit Care Med 154(4 Pt 1):1055-60
110. Rahman I and MacNee W (1996b) Role of oxidants / antioxidants in smoking-induced
airways diseases. Free Radic Biol Med 21:669-681
111. Rahman I, Antonicelli F, MacNee W (1999) Molecular mechanism of the regulation of
glutathione synthesis by tumour necrosis factor-α and dexamethasone in human alveolar
epithelial cells. J Biol Chem 274:5088-5096
112. Richardson G.E et al. (1993) Smoking cessation after successful treatment of small-cell
lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern
Med 119(5):383-90
113. Richman P. G and Meister A (1975) Regulation of γ-glutamylcysteine synthetase by
nonallosteric feedback inhibition by glutathione.  J BioI Chem 250: 1422-1426
114. 114.Sancar A (1996) DNA excision repair. Annu Rev Biochem 65:43-81
115. Sachs C.W et al. (1995) Partial inhibition of multidrug resistance by safingol is
independent of modulation of P-glycoprotein substrate activities and correlated with
inhibition of protein kinase C. J Biol Chem 270:26639-26648
116. Sato W et al. (1990) Staurosporine, a potent inhibitor of C-kinase, enhences drug
accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 173:1252-1257
- 95 -
117. Shen H et al. (2003) Smoking, DNA repair capacity and risk of non- small-cell lung
cancer. Int J Cancer 107(1):84-8
118. Shen H et al. (2002) A novel polymorphism in human cytosine DNA-methyltransferase-
3B promoter is associated with an increased risk of lung cancer. Cancer Res 62(17):4992-
5
119. Shopland DR (1995) Tobacco use and its contribution to early cancer mortality with a
special emphasis on cigarette smoking. Environ Health Perspect 103 Suppl 8 :131-42
120. Siafakas N.M et al. (1995) Optimal assessment and management of chronic obstructive
pulmonary disease (COPD). A consensus statement of the European Respiratory Society.
Eu Respir J 8
121. Singer B and Hang B (1997) What structural features determine repair enzymes
specificity and mechanism in chemically modified DNA? Chem Res Toxicol 10:713-32
122. Snider G (1989) Chronic obstructive pulmonary disease: risk factors, pathophysiology
and pathogenesis. Annu. Rev. Med. 40: 411-429
123. Spivack S.D et al. (1997) The molecular epidemiology of lung cancer. Crit Rev Toxicol
27:319-65
124. Stauble B et al. (1994) Modulation of activator protein-1 (AP-1) transcription factor and
protein kinase C by hydrogen peroxide and D-α-tocopheral in vascular smooth muscle
cells. Eur J Biochem 226:393-402
125. Stein E.A et al. (1998) Nicotine-induced limbic cortical activation in the human brain:
functional MRI study. Am J Psychiatry 155(8):1009-15
126. Stern M.C et al. (2002) XPD codon 751 polymorphism, metabolism genes, smoking, and
bladder cancer risk. Cancer epidemiol Biomarkers Prev. 11(10 Pt 1):1004-11
127. Sun W. M et al. (1996) Regulation of γ-glutamylcysteine synthetase by protein
phosphorylation. Biochem J 320: 321-328
128. Sullivan S.G et al. (1994) Effects of hydrogen peroxide on protein tyrosine phosphatase
activity in HER 14 cells. Free Radic Biol Med. 16:399-403
129. Sundberg K et al. (1997) Glutathione conjugation of bay- and fjord-region dio1 epoxides
of polycyclic aromatic hydrocarbons by glutathione transferase M1-1 and P 1-1. Chem
Res Toxicol 10:1221-7
130. Tang D.L et al. (1998) Associations between both genetic and environmental biomarkers
and lung cancer: evidence of a greater risk of lung cancer in women smokers.
Carcinogenesis 19:1949-53
131. Tomonari A et al. (1997) Identification of cis-acting DNA elements of the human gamma-
glutamylcysteine synthetase heavy subunit gene. Biochem. Biophys Res Commun
232:522-527
132. Trochon V et al. (1996) Evidence of involvement of CD44 in endothelial cell
proliferation, migration and angiogenesis in vitro. Int J Cancer 66:664-668
133. Tucker M.A et al. (1997) Second primary cancers related  to smoking and treatment of
small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 89(23):1782-8
134. Urata Y et al. (1996) Long exposure to high glucose concentration impairs the responsive
expression of gamma-glutamylcysteine synthetase by interleukin-1beta and tumour
necrosis factor-alpha in mouse endothelial cells. J Biol Chem. 271: 15146-15152
135. Van Herwaarden C.L.A et al. (1996) COPD: diagnosis and treatment. Excerpta Medica
136. Vargas-Roig L.M et al. (1998) Heat shock protein expression and drug resistance in breast
cancer patients treated with induction chemotherapy. Int J Cancer (United States)
79(5)p468-75
137. Villard P.H et al. (1998) Effects of tobacco smoke on the gene expression of the Cyp1a,
Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to strand breaks
of DNA. Toxicol Appl Pharmacol 148(2):195-204
138. Volm M et al. (1995a) Up-regulation of heat shock protein 70 in adenocarcinomas of the
lung in smokers.  Anticancer Res 15(6B):2607-9
139. Volm M et al. (1995b) Heat shock (HSP 70) and resistance proteins in non-small-cell lung
carcinomas. Cancer Lett 95(1-2):195-200
- 96 -
140. Volm M et al. (1997) Expression of lung resistance-related protein (LRP) in non-small-
cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin
resistance. Anticancer Drugs 8(10):931-6
141. Volm M and Pommerenke E.W (1995) Associated Expression of Protein Kinase C with
Resistance to Doxorubicin in Human Lung Cancer. Anticancer Research 15:463-466
142. Wang X et al. (1999) Carcinogen exposure, p53 alteration, K-ras mutation in synchronous
multiple primary lung carcinomas. Cancer 85(8):1734-9
143. Wei Q et al. (1996) Reduced DNA repair capacity in lung cancer patients. Cancer Res
56(18):4103-7
144. Wigren T et al. (1997) A practical prognostic index for inoperable non-small-cell lung
cancer. J Cancer Res Clin Oncol 123(5) :259-66
145. Wolf P et al. (2001) O6-Methylguanine-DNA methyltransferase promoter
hypermethylation shifts the p53 mutational spectrum in non-small-cell lung cancer.
Cancer Res 61(22):8113-7.
146. Wong G. H and Goeddel D.V (1988) Induction of manganous superoxide dismutase by
tumour necrosis factor: possible protective mechanism. Science 242: 941-944
147. Wu X et al. (1997) Association between cytochrome P4502E1 genotype, mutagen
sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis
18(5):967-73
148. Wu X et al. (2003) XPA polymorphism associated with reduced lung cancer risk and
modulating effect on nucleotide excision repair capacity. Carcinogenesis 24(3):505-9
149. Xing D et al. (2002) Polymorphisms of the DNA repair gene XPD and risk of lung cancer
in a Chinese population. Lung cancer 38(2):123-9
150. Xing D.Y et al. (2003) Association of genetic polymorphisms in the DNA repair gene
XPD with risk of lung cancer and oesophageal cancer in a Chinese population in Beijing.
Zhongua Yi Xue Yi Chuan Xue Za Zhi 20(1):35-8
151. Yamaziki H et al. (1992) Cytochrom P450 2E1 and 2A6 enzymes as major catalysts for
metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in
human liver microsomes. Carcinogenesis 13:1789-1794
152. Yin L et al. (2000) Alterations of extracellular matrix induced by tobacco smoke extract.
Arch Dermatol Res 292(4):188-94
153. Yoshida T, Matsui K, Masuda N, Kusunoki Y, Takada M et al. (1996) Risks of second
primary cancer in two-year survivors of small-cell lung cancer. Nihon Kiyobu Shikkan
Gakkai Zasshi 34(7):741-6
154. Young M.R. I et al. (1992) Activation of protein kinase A increases the in vitro invasion,
migration, and adherence to reconstituted basement membrane by Lewis lung carcinoma
tumour cells. Invasion Metastasis 12:253-263
155. Young M.R.I et al (1993) Protein phosphatases limit tumour motility. Int. J. Cancer
54:1036-1041
156. Yu C.J et al. (1996) Overexpression of MUC-5 genes is associated with early post-
operative metastasis in non-small-cell lung cancer. Int J Cancer 69(6):457-65
157. Yu C.J et al, (1997) Sialomucin expression is associated with erbB-2 oncoprotein
overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Am J
Respir Crit Care Med 155(4): 1419-27
- 97 -
13. Acknowledgments (In German Language)
      = Danksagung
An erster Stelle möchte ich meinem Betreuer, Herrn Prof. Dr. med. G.
Schlimok, Chefarzt der II. Medizinischen Klinik am Klinikum Augsburg,
meinen tiefen Dank für seine Hilfe und Unterstützung ausdrücken. Prof. Dr.
Schlimok widmete seine kostbare Zeit, um mir bei dieser Arbeit zum Erfolg
zu verhelfen. Dafür rechtherzlichen Dank!
Herrn Dr. med. M. Sandherr, Oberarzt in der II. Medizinischen Klinik am
Klinikum Augsburg, gilt mein besonders herzlicher Dank für seine
Mitbetreuung. Seine Freundlichkeit, Geduld, Kompetenz, und vor allem
konstruktive Kritik bei der Verfassung dieser Arbeit waren mir sehr
hilfreich.
Herrn PD Dr. med. T. Beinert möchte ich, für seine Betreuung zu Beginn
dieser Promotionsarbeit im Jahr 2000 in der II. Medizinischen Klinik mit
Schwerpunkt Onkologie und Hämatologie am Universitätsklinikum
(Charité) der Humboldt-Universität zu Berlin, auch danken.
Mein herzlicher Dank geht an Frau G. Siebert vom Institut für Medizinische
Informatik und Biostatistik an der Humboldt-Universität zu Berlin für ihre
wertvolle Unterstützung bei der statistischen Auswertung der Patientendaten
und Interpretation einiger Ergebnisse.
Ferner möchte ich Herrn Dr. rer. nat. M. Fleischhacker vom
Universitätsklinikum (Charité) der Humboldt-Universität zu Berlin für seine
Unterstützung und hervorragendes Zusammenarbeiten in unserer
wissenschaftlichen Arbeitsgruppe "Bronchialkarzinom" danken.
Vielen herzlichen Dank!
- 98 -
14. Curriculum  vitae (In German Language)






Schulische Ausbildung (Dar es Salaam - Tansania)
y± Ubungo primary school
y± Forodhani ordinary level secondary
school






- Praktisches Jahr (PJ)
y± Gynäkologie und Geburtshilfe;
Muhimbili University College of Health
Sciences (Dar es Salaam - Tansania),
Prof. Kaisi und Dr. Ngwalle
y± Innere Medizin; Fachkrankenhaus für
Lungenheilkunde und Thoraxchirurgie
(FLT, Berlin-Buch), Prof. Dr. med.
Lichey und Dr. med. Deppermann
y± Chirurgie; DRK Kliniken Berlin -
Westend, Prof. Dr. med. Gögler
- Examen
y Ärztliche Vorprüfung
y 1. Abschnitt der Ärztlichen Prüfung
y 2. Abschnitt der Ärztlichen Prüfung
y 3. Abschnitt der Ärztlichen Prüfung
   (Staatsexamen)
- 99 -
Promotion
y09/2000 Beginn der Doktorarbeit bei Herrn PD
Dr. med. T. Beinert, II. Medizinischen
Klinik mit Schwerpunkt Onkologie und
Hämatologie des Universitätsklinikums
(Charité) der Humboldt-Universität zu
Berlin
Fortführung der Doktorarbeit unter der
Leitung von Herrn Prof. Dr. med. G.
Schlimok und Dr. med. M. Sandherr in
der II. Medizinischen Klinik des
Klinikums Augsburg
- Thema: Retrospective study to evaluate the
prognostic effect of smoking cessation in
patients with advanced lung cancer under
palliative anticancer therapy
Berufliche Tätigkeiten
y± Beginn der Tätigkeit als Arzt im
Praktikum (AiP) bei Herrn Prof. Dr.




y± Arbeiten als Assistenzarzt in der Inneren
Medizin bei Herrn Dr. med. D. Eckardt
im Achenbach-Kreiskrankenhaus in
Königs Wusterhausen in Brandenburg
yVHLW        10/2001 Arbeiten   als   Assistenzarzt   bei  Herrn
Prof. Dr. med. G. Schlimok in der II.
Medizinischen Klinik des Klinikums
Augsburg
